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Summary 
 
The Mediator of transcriptional regulation is the central coactivator that enables a 
response of RNA polymerase II (Pol II) to activators and repressors. Yeast Mediator 
has a size of more than one MDa and consists of 25 different polypeptides. 
Biochemical studies defined three Mediator modules in yeast, the head (MED17) the 
middle (MED9/MED10) and the tail (MED15) modules. During this work, an E.coli 
coexpression-copurification system was developed, which allowed to study pairwise 
interactions of Mediator middle module subunits. With the help of this system I 
reconstituted a complex of two essential and conserved yeast Mediator middle module 
proteins, the MED7/MED21 heterodimer, and solved its crystal structure. The 
heterodimer forms an extended structure, which spans one third of the Mediator length, 
and almost the diameter of Pol II. It shows a four helix bundle and a coiled-coil 
protrusion connected by a flexible hinge. Multiple conserved patches can be identified 
on the surface, which allow for assembly of the middle module. A combination of the 
coexpression-copurification system and assembly of subcomplexes allowed the 
reconstitution of a five-subunit Mediator middle module subcomplex. The reconstituted 
subcomplex is able to bind Pol II in vitro. MED6 associates with the middle module 
and forms a bridge to the head module. The potential flexibility of this bridge and the 
MED7/MED21 hinge can account for changes in Mediator structure upon its binding to 
Pol II or to activators.  
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1 INTRODUCTION
1 Introduction
1.1 RNA polymerases
Transcription is the fundamental process of RNA synthesis from a DNA template. The
basic transcription reaction is very similar in all organisms. RNA polymerases are the
enzymes which transcribe DNA into RNA. Sequence and structural comparisons re-
veal the evolutionary conservation of the overall architecture of RNA polymerases in
the three kingdoms of life. The five subunits of the bacterial polymerase form a core
homologous to the yeast RNA polymerase core (reviewed in Cramer, 2002). Archaeal
and eukaryotic RNA polymerases are multi-subunit enzymes, contain at least ten sub-
units and are highly homologous. While bacteria and archaea have only one RNA
polymerase, eukaryotes have three enzymes to synthesize different classes of RNA.
RNA polymerase I (Pol I) is mainly responsible for the synthesis of ribosomal RNA
(rRNA), RNA polymerase II (Pol II) transcribes protein coding genes into precursor
mRNA, and RNA polymerase III (Pol III) transcribes one rRNA and all transfer RNAs.
Bacterial, archaeal and eukaryotic polymerases have their own set of transcription fac-
tors. In bacteria the most prominent accessory factor is the σ70 factor. It recognizes
the promoter sequences of house keeping genes, promotes conformational changes
upon initiation and interacts directly with regulatory proteins (reviewed in Murakami
and Darst, 2003). In archaea and eukaryotes the function of the σ subunit has been
replaced by an abundance of transcription factors. The archaeal polymerase relies
on two essential general transcription factors, the TATA binding protein (TBP) and
TFB. Transcriptional regulators seem to be adopted largely from bacterial systems and
large coactivator complexes are absent (reviewed in Geiduschek and Ouhammouch,
2005; Ouhammouch, 2004). Eukaryotic Pol II has been extensively characterized,
both biochemically and structurally. Transcription of protein-coding genes by Pol II
is dependent on additional factors. Pol II associates with the five general transcrip-
tion factors TFIIA, -B, -D, -E, -H, coactivators, mRNA processing factors and RNA
export factors (Woychik and Hampsey, 2002; Hahn, 2004). The crystal structures of
Pol II, Pol II with nucleic acids and Pol II with the general transcription factors TFIIS
and TFIIB have been determined (Cramer et al., 2001; Armache et al., 2005; Bushnell
et al., 2004; Kettenberger et al., 2004). EM reconstructions of a Pol II/TFIIF complex
have also been achieved (Chung et al., 2003; Asturias, 2004).
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1.2 The RNA polymerase II transcription cycle
Transcription catalyzed by Pol II involves multiple steps. The transcription cycle can
be divided in initiation, elongation, termination and reinitiation. During initiation,
gene specific regulatory factors recruit chromatin remodeling factors or coactivators
that interact directly with the transcriptional machinery to promote preinitiation com-
plex (PIC) assembly. Coactivators, such as Mediator, transmit regulatory signals to the
polymerase. General transcription factors TFIIB, -D, -E, -F, and H mediate promoter
recognition and opening. Initially, in the PIC all factors and the polymerase are bound
to the promoter in a so-called “closed” complex. Transition to the “open” complex
involves DNA melting, requires ATP hydrolysis and in the presence of NTPs the poly-
merase initiates transcription. After the synthesis of about 30 nucleotides, the poly-
merase leaves the initiation complex and enters the elongation phase (promoter clear-
ance). Elongation factors ensure efficient mRNA production. Chromatin remodeling
factors, RNA processing and polyadenylation factors are recruited to the polymerase.
Most of the factors which are involved in initiation remain bound to the promoter in
a scaffold complex (Yudkovsky et al., 2000). The scaffold complex is thought to pro-
mote fast transcription reinitiation at a previously transcribed gene (Figure 1; Hahn,
2004).
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Figure 1: Transcription initiation and reinitiation pathways for Pol II. (adopted from
Hahn, 2004)
1.2.1 The general transcription factors and transcription initiation
During transcription initiation the basal transcription machinery is assembled at the
core promoter, the minimal sequence which is required for basal transcription. The
core promoter includes defined sequence elements within 35 bp upstream the transcrip-
tion start site in human and drosophila, 40 to 120 bp in yeast. These elements include
the TATA element (TBP binding), TFIIB recognition element (BRE), Initiator element
(INR) and Downstream promoter element (DPE) (reviewed in Smale and Kadonaga,
2003). The most prominent core promoter sequence is the TATA element which is
bound by TBP. TBP binding promotes DNA bending and seems to be the first step in
transcription machinery assembly (Kim et al., 1993). TBP belongs to the 15 subunit
TFIID complex. TFIIA binding stabilizes the TBP/DNA complex (Geiger et al., 1996;
Tan et al., 1996). TFIIB directly contacts TBP as well as the DNA in the complex
(Nikolov et al., 1995). Polymerase and TFIIF can then assemble with the preformed
complex. After the recruitment of TFIIE and TFIIH, ATP dependent promoter opening
can occur. The helicase of TFIIH is responsible for open complex formation. Dur-
ing this process the DNA template strand is positioned within the polymerase active
site. TFIIH also phosphorylates the C-terminal domain (CTD) of the largest subunit
7
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Factor Function
TFIIA Stabilizes TBP and TFIID-DNA binding. Blocks transcription in-
hibitors. Positive and negative gene regulation.
TFIIB Binds TBP, Pol II and promoter DNA. Helps fix the transcription start
site.
TFIID TBP Binds TATA element and deforms promoter DNA. Platform for assem-
bly of TFIIB, TFIIA and TAFs.
TAFs Binds INR and DPE elements. Target of regulatory factors.
Mediator Binds cooperatively with Pol II. Kinase and acetyl transferase activ-
ity. Stimulates basal and activated transcription. Target of regulatory
factors.
TFIIF Binds Pol II and is involved in Pol II recruitment to PIC and in open
complex formation.
TFIIE Binds promoter near transcription start.
TFIIH Functions in transcription and DNA repair. Kinase and two helicase
activities. Essential for open complex formation.
SAGA Contains Histone acetyl-transferase and Ubiquitin protease activity. In-
teracts with TBP and TFIIA. Target of activators.
Table 1: General transcription factors and coactivators in the yeast S. cerevisiae.
(adapted from Hahn, 2004)
of Pol II thereby enabling polymerase dissociation from the PIC (Table 1). Basal tran-
scription has been reconstituted in vitro by adding general transcription factors and
polymerase to the DNA template (Sayre et al., 1992).
1.2.2 The C-terminal domain of RNA polymerase II is modified during the tran-
scription cycle
Pol II Rbp1 contains a CTD which consists of 25 to 52 heptad repeats, according
to the organism, with the consensus sequence YSPTSPS (Corden, 1990). This con-
sensus sequence acts as a platform for assembly of factors that regulate transcription
initiation, elongation, termination and mRNA processing. CTD phosphorylation or
dephosphorylation coordinates the transcription cycle (Dahmus, 1996). During initia-
tion, Mediator binding to Pol II requires a dephosphorylated CTD. CTD phosphoryla-
tion breaks Pol II-Mediator interactions, resulting in an elongating Pol II and a scaffold
complex bound to the promoter. The elongating Pol II has a phosphorylated CTD. The
CDK/Cyclin pairs of TFIIH (CDK7/CyclinH) and Mediator (CDK8/CyclinC) phos-
phorylate the CTD during initiation. The CDK/Cyclin pair of pTEFb (CDK9/CyclinT)
8
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phosphorylates the CTD during elongation (Pinhero et al., 2004). Proteins required
for mRNA processing bind to the phosphorylated CTD. The phosphatases Fcp1, Scp1
(Lin et al., 2002; Kamenski et al., 2004) and Ssu72 (Meinhart et al., 2003b) dephos-
phorylate the CTD and thereby enable the interaction with the scaffold complex and
transcription reinitiation.
The CTD, together with a linker region, is disordered in Pol II crystal structures
(Cramer et al., 2001). NMR and CD studies also show a largely unstructured na-
ture of the free CTD (reviewed in Meinhart et al., 2005). The CTD could provide a
platform for many different interactions with structurally different target proteins via
an induced fit mechanism (Lima, 2005). Only peptide structures of the phosphory-
lated CTD in complex with Pcf11 (Meinhart and Cramer, 2004), Ctg1 (Fabrega et al.,
2003) and Pin1 (Verdecia et al., 2000) have been determined. The CTD in the three
structures is differentially modified and shows different conformations (reviewed in
Meinhart et al., 2005; Fabrega et al., 2003).
The non-phosphorylated CTD is required for Mediator binding. In yeast the CTD is
necessary for the formation of a stable Pol II/Mediator complex (Myers et al., 1998;
Asturias et al., 1999), and CTD-Mediator interaction is needed for Mediator function,
since yeast Mediator cannot stimulate transcription by a CTD-less Pol II. The human
Mediator Complex CRSP (cofactor required for Sp1) also interacts with the CTD and
adopts a specific CTD bound conformation (Naar et al., 2002). However, there is no
indication on how the non-phosphorylated CTD might interact with Mediator. Larger
isoforms of Mediator such as the Mediator-like complexes NAT (negative regulator
of activated transcription) and SMCC (Srb/Med-containing cofactor complex) can act
independently of the CTD (Sun et al., 1998; Gu et al., 1999). Both Complexes include
the CTD kinase of the CDK8/CyclinC Module.
1.3 Regulated transcription
Regulation of expression of protein-coding genes is very important during cell growth
and differentiation. Gene expression regulation occurs at many different levels, includ-
ing transcription, RNA processing, mRNA export, translation as well as mRNA and
protein stability. A very strongly regulated process however, is transcription initiation.
Regulation of bacterial transcription requires transcriptional activators or repressors
which bind to DNA elements and directly exert their function on the bacterial RNA
9
1.4 Mediator and transcription regulation 1 INTRODUCTION
polymerase. Transcription regulation in eukaryotes is more elaborate, since the orga-
nisms are more complex (Levine and Tjian, 2003). Multiple regulatory signals which
come from DNA bound, gene specific activators or repressors have to be processed
and transmitted to the Pol II transcription machinery. These gene specific transcrip-
tion regulators recruit multi-protein coactivators, via direct protein-protein interactions
(reviewed in Kadonaga, 2004; Naar et al., 2001). Coactivators can act indirectly or
directly to regulate the activity of the Pol II transcription machinery at the core pro-
moter. Chromatin related coactivators regulate transcription indirectly by nucleosome
remodeling or by covalent Histone modifications. Within the Pol II transcriptional
machinery, Mediator and TFIID are coactivators which are targets of transcriptional
regulators. These two coactivators regulate transcription directly, by forming an inter-
face between regulators and Pol II in complex with the general transcription factors.
Over the last decade evidence from many laboratories has converged on Mediator as
the central Pol II coactivator (Myers and Kornberg, 2000; Malik and Roeder, 2000;
Bjorklund and Gustafsson, 2004; Kornberg, 2005; Malik and Roeder, 2005).
1.4 Mediator and transcription regulation
Mediator was discovered in the yeast S. cerevisiae by its ability to enable activated
transcription in an in vitro system containing Pol II and the general transcription fac-
tors (Flanagan et al., 1991; Kelleher et al., 1990; Kim et al., 1994). Human Mediator
was described in a screen for transcription cofactors (Meisterernst et al., 1991; Kret-
zschmar et al., 1994). Genome-wide studies showed that Mediator is required for
regulated transcription of the majority of yeast genes (Holstege et al., 1998). Mediator
promotes initiation complex assembly through activator-Mediator, Mediator-Pol II and
Mediator-general transcription factor contacts (Cantin et al., 2003). Initial attempts to
purify yeast Mediator yielded a “holoenzyme”, consisting of Mediator in complex with
Pol II and loosely associated factors of the basal transcription machinery (Hengartner
et al., 1995; Wilson et al., 1996). These findings lead to the proposition that it is a
“holoenzyme” which is recruited to the promoter upon gene induction (Kim et al.,
1994). Later studies on the in vivo distribution of Pol II and Mediator on Drosophila
polytene chromosomes (Park et al., 2001b) showed that the two complexes do not co-
localize. Recruitment of Mediator precedes the recruitment of Pol II (Bhoite et al.,
2001; Cosma et al., 2001). Accordingly, about 70 % of Mediator in yeast occurs as
10
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free Mediator and only 30 to 40 % as Mediator/Pol II complex (Liu et al., 2001; Takagi
et al., 2005). Mediator also stimulates basal transcription (Baek et al., 2002; Mittler
et al., 2001). The yeast Mediator comprises 25 polypeptide subunits: 11 subunits are
essential and 22 are at least partially conserved in sequence throughout eukaryotes
(Bourbon et al., 2004; Boube et al., 2002). Mediator-like complexes were isolated
from human cells (Fondell et al., 1996; Sun et al., 1998; Naar et al., 1999; Rachez
et al., 1999; Ryu and Tjian, 1999), mouse (Jiang et al., 1998), fission yeast (Spahr
et al., 2000) and Drosophila (Park et al., 2001a). Comparison of the different Media-
tors has led to the identification of homologues of most of the yeast Mediator subunits
(Boube et al., 2002; Bourbon et al., 2004; Table 2).
1.4.1 Mediator complexes have a modular architecture
The Mediator subunit architecture was inferred from biochemical, genetic, and elec-
tron microscopic studies. Biochemical studies defined three Mediator submodules,
which were stable even in the presence of elevated urea concentrations: the head mod-
ule (MED17/Srb4), the middle module (MED9/MED10) and the tail module
(Rgr1/MED14), which were tentatively correlated with three density lobes in electron
microscopic images. The head, middle and tail modules are found in most Mediator
preparations. An additional module, the CDK8/CyclinC module is only partially asso-
ciated to the Mediator (Samuelsen et al., 2003). The yeast Mediator has been purified
as a single multisubunit complex. On the contrary, different purifications of mam-
malian Mediator complexes often have different compositions. Purification schemes
based on interactions with transcriptional activators (TRAP (Fondell et al., 1996), ARC
(Naar et al., 1999), DRIP (Rachez et al., 1999), E1A (Boyer et al., 1999)), homologous
subunits to yeast Mediator (SMCC (Gu et al., 1999), NAT (Sun et al., 1998)) and coac-
tivator activity (CRSP (Ryu and Tjian), PC2 (Malik et al., 2000)) purified complexes
of different subunit compositions. Even though there are differences in the prepara-
tions, all complexes contain a core of subunits which have orthologous in S. cerevisiae
Mediator (Taatjes et al., 2004a). In addition, proteomic analysis of affinity-purified
Mediator, with the affinity tag on different subunits, resulted in one complex with all
identified subunits present (Sato et al., 2004). These observations indicate that the
purified complexes probably represent versions of the same cellular entity (Conaway
et al., 2005).
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new Name S. cerevisiae (previous name) H. sapiens (previous name) location
MED1 Med1 TRAP220 middle
MED2 Med2 - tail
MED3 Pgd1/Hrs1/Med3 - tail
MED4 Med4 TRAP36/DRIP36 middle
MED5 Nut1 - middle/tail
MED6 Med6 hMed6/Drip33 head
MED7 Med7 hMed7/Drip34 middle
MED8 Med8 Arc32 head
MED9 Cse2/Med9 Med25 middle
MED10 Nut2/Med10 hNut2/hMed10 middle
MED11 Med11 HSPC296 head
MED12 Srb8 TRAP230/DRIP240 kinase
MED13 Srb9 TRAP240/DRIP250 kinase
MED14 Rgr1 TRAP170/DRIP150/CRSP150 tail
MED15 Gal11 ARC105 tail
MED16 Sin4 TRAP95/DRIP92 tail
MED17 Srb4 TRAP80/DRIP77/CRSP77 head
MED18 Srb5 p28b head
MED19 Rox3 LCMR1 head
MED20 Srb2 hTRFP/p28a head
MED21 Srb7 hSrb7/p21 middle
MED22 Srb6 Med24/Surf5 head
MED23 - TRAP150β/DRIP130/CRSP130/hSur2 ?
MED24 - TRAP100/DRIP100/CRSP100 ?
MED25 - ARC92/ACID1 ?
MED26 - ARC70/CRSP70 ?
MED27 - TRAP37/CRSP347 ?
MED28 - Fksg20 ?
MED29 - Hintersex ?
MED30 - TRAP25 ?
MED31 Soh1 hSoh1 middle
CDK8 Srb10/Ssn3/Ume5 hSrb10/CDK8 kinase
Cyclin C Srb11/Ssn8/Ume3 hSrb11/CycC kinase
Table 2: Mediator subunit nomenclature according to Bourbon et al., 2004.
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1.4.2 The role of Mediator during transcription initiation and reinitiation
Mediator is recruited by activators to genes in a separable step from Pol II recruitment
(Cosma et al., 2001), and it is thought to remain near the promoter, to facilitate tran-
scription reinitiation (Liu et al., 2001; Yudkovsky et al., 2000). After the first transcrip-
tion cycle, the scaffold complex, consisting of activator, Mediator and the general
transcription factors TFIID, TFIIA, TFIIE and TFIIH, provides a platform for tran-
scription reinitiation by Pol II. The scaffold complex enables genes to be transcribed
more rapidly, because the slow step of PIC assembly is omitted. Transcription activa-
tion domains can stabilize the scaffold complex in vitro (Yudkovsky et al., 2000). An
additional activation-independent function in initiation complex formation and tran-
scription reinitiation has been attributed to the yeast Mediator tail module (Reeves and
Hahn, 2003).
The Mediator CDK8/CyclinC module phosphorylates the CTD at serine 5 and stimu-
lates the kinase activity of the general transcription factor TFIIH, which is the primary
CTD kinase. CTD phosphorylation triggers the transition from transcription initiation
to elongation (Kim et al., 1994; Li and Kornberg, 1994; Serizawa et al., 1993). In addi-
tion to CTD phosphorylation, TFIIH also phosphorylates the Mediator subunits MED4
and MED14 (Liu et al., 2004; Guidi et al., 2004), and CDK8/CyclinC phosphorylate
Bdf1 and Taf2 (TFIID). The function of Mediator and TFIIH are linked to each other
and both govern the CTD-dependent transcription in yeast extracts (Nair et al., 2005).
Inhibition of the two kinases inhibits dissociation of the PICs (Liu et al., 2004), and
therefore transcription initiation.
1.4.3 Structural information on Mediator complexes
Electron microscopy has been used to investigate the structure of Mediator alone and
in complex with Pol II, activators or the CTD. Mediator unfolds in the presence of
Pol II and adopts an extended conformation in which it wraps around the polymerase
(Asturias et al., 1999). The whole polymerase is needed for Mediator unfolding since
neither the polymerase without the CTD nor the CTD alone are able to induce complete
unfolding. In this extended conformation, the biochemically defined head, middle and
tail modules of Mediator can be distinguished. The fourth module, the CDK8/CyclinC
module, was not present in these studies. In order to attribute the biochemically
defined modules in the EM reconstructions, the wild type strain was compared to a
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MED16 deletion mutant (Dotson et al., 2000; Davis et al., 2002). The whole tail mod-
ule (MED2, MED3, MED15, MED16) is absent from Mediator in such a mutant. In
addition, interaction maps obtained from yeast two hybrid analysis (Uetz et al., 2000;
Guglielmi et al., 2004; Ito et al., 2001), coexpression in insect cells (Han et al., 2001;
Kang et al., 2001), split ubiquitin assay (Gromoller and Lehming, 2000a) and urea
washes (Han et al., 2001) gave indications about the Mediator subunit organization
and allowed the attribution of the head and the middle module. No direct mapping of
individual Mediator subunits has been done in yeast so far.
EM structural analysis of murine and human Mediator complexes revealed an overall
structure similar to the yeast complex (Dotson et al., 2000). The CDK8/CyclinC mod-
ule was not present in the structures of yeast and murine complexes, but is present in
some structures of the human complex (Taatjes et al., 2002). There is no EM struc-
ture of a human Pol II/Mediator complex, but the effect of activators and the CTD on
these complexes has been tested (Naar et al., 2002; Taatjes et al., 2002; Taatjes and
Tjian, 2004). There are structural changes upon binding of each of the activators as
well as upon binding of the CTD or the CDK8/CyclinC module. These conformational
changes are relatively small compared to the unfolding that yeast Mediator undergoes
upon binding to Pol II. The functional role of each of these conformational changes
has not been investigated yet. They could represent a way to transfer signals from
different activators to the polymerase (Chadick and Asturias, 2005). Furthermore,
activators seem to stabilize the scaffold complex and thereby facilitate transcription
reinitiation (Reeves and Hahn, 2003; Wang et al., 2005). It has been speculated that
conformational changes have a role in PIC isomerization to allow promoter melting or
promoter clearance (Struhl, 2005). In summary, even low resolution (∼35 Å) electron
microscopic studies show that Mediator undergoes strong structural changes upon in-
teraction with Pol II and with transcription activators. The causes and consequences of
these changes are however poorly understood, and the molecular mechanism of Medi-
ator remained enigmatic, mainly because of a complete lack of detailed high resolution
structural information.
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1.5 The yeast Mediator proteins
1.5.1 The Mediator head module
The yeast Mediator head module consists of the proteins MED6, MED8, MED11,
MED17 (Srb4), MED18 (Srb5), MED19 (Rox3), MED20 (Srb2) and MED22 (Srb6)
(Boube et al., 2002). All four Srb genes were identified as dominant gain-of-function
suppressors of a CTD truncation mutant (Thompson et al., 1993). While MED18 and
MED20 are none essential genes (Nonet and Young, 1989), MED17 and MED22 are
essential (Thompson et al., 1993). Whole genome expression profiles for MED17
and MED22 show a general dependence of Pol II transcription on these genes (Hol-
stege et al., 1998). MED18 and MED20 form a subcomplex, are required for the
regulation of a specific subset of genes (van de Peppel et al., 2005), and seem to
have a role in transcription initiation (Ranish et al., 1999). The other head mod-
ule proteins (MED6, MED8, MED11, MED19) have been identified by peptide se-
quencing of purified complexes. MED6 is the highest conserved subunit of the head
module (34 % homology between yeast and human). MED6, MED8, MED11 and
MED19 are essential in S. cerevisiae and bind directly to the MED17 subunit, which
plays a scaffold role within the module. S. cerevisiae MED8 is phosphorylated in the
Mediator complex and as been shown to bind DNA at certain regulatory elements
(Chaves et al., 1999). In addition to its occurrence in the Mediator, the mammalian
MED8 can assemble with an elongin and a ringfinger protein (Cul2 and Rbx1, respec-
tively) to reconstitute a Ubiquitin ligase elongin BC complex (Brower et al., 2002).
Recombinant complexes of MED17/MED18/MED20/MED22 (Koh et al., 1998) and
MED6/MED8/MED11/MED17/MED18/MED19/MED20/MED22 (Kang et al., 2001)
have been obtained from baculo-virus expression systems. The latter binds to the Pol II
CTD as well as to TBP and TFIIB, and it is able to stimulate basal transcription (two
to three fold) but not activated transcription (Kang et al., 2001). The reconstituted
head module can be associated with a reconstituted middle module to give a core Me-
diator complex. All head module proteins have homologous counterparts in higher
eukaryotes.
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1.5.2 The Mediator middle module
The Mediator middle module consists of the proteins MED1, MED4, MED7, MED9
(Cse2), MED10 (Nut2), MED21 (Srb7), MED31 (Soh1) and possibly MED5 (Nut1).
MED4, MED7, MED9, MED10 and MED21 are essential in yeast while MED1,
MED5, MED9 and MED31 are not essential (reviewed in Myers and Kornberg, 2000).
The yeast Mediator middle module can be further divided into two biochemically sta-
ble submodules: the MED9 (MED1, MED4 MED9) and the MED10 (MED7, MED10,
MED21) submodules (Kang et al., 2001; Han et al., 2001). Mutations of proteins in
the two biochemical submodules have distinct phenotypes of transcriptional activation
and repression (Han et al., 1999). In addition, Mediator purified from a MED9 dele-
tion strain seems to be defective in stimulation of basal transcription (Liu et al., 2001).
MED5 is the only protein of the middle module which has no homologous in higher
eukaryotes, and is present only in a subpopulation of yeast Mediator. The MED5 pro-
tein has a histone acetyl transferase activity (Lorch et al., 2000). Its interactions with
the middle module are not clear, even though yeast two hybrid screens indicate an in-
teraction with MED1 in the middle and MED16 in the tail module (Guglielmi et al.,
2004).
The MED31 protein was only recently discovered to be part of the Mediator middle
module (Guglielmi et al., 2004; Linder and Gustafsson, 2004). Due to interactions with
MED10 and MED21 observed by yeast two hybrid assays, MED31 most likely belongs
to the MED10 submodule. It is note worthy that MED31 has 50 % sequence homo-
logy between yeast and human and is the best conserved core Mediator subunit. The
MED31 protein is conserved also in Giardia intestinalis and Plasmodium falciparum
which lack the CTD heptapeptide repeat (Linder and Gustafsson, 2004; Stiller and
Hall, 2002). MED31 has therefore been suggested to be an ancient Mediator protein
involved in signal transmission from regulators to polymerases in eukaryotes that di-
verged before the evolution of the CTD and the remaining Mediator subunits.
The other three proteins of the MED10 submodule, MED7, MED10, and MED21
are also highly conserved between yeast and human Mediator with 40, 39 and 44 %
conservation, respectively. MED21 (Srb7) is the only protein of the core Mediator that
has been discovered as a recessive mutation in a screen for mutants, which are able to
restore viability of CTD truncations. Other recessive mutations found in this screen
encode for proteins in the Mediator CDK8/CyclinC module.
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Association of the Mediator middle module with the head module seem mediated
through MED21 (Guglielmi et al., 2004; Gromoller and Lehming, 2000a). A reconsti-
tuted yeast Mediator middle module, containing all subunits but MED5 and MED31,
was able to associate with the general transcription factors TBP, TFIIB and TFIIE as
well as with the CTD (Kang et al., 2001).
1.5.3 The Mediator tail module
The Mediator tail module contains MED2, MED3 (Pgd1/Hrs1), MED14 (Rgr1), MED15
(Gal11), MED16 (Sin4). Of these subunits, only the N-terminus of MED14 is essential
for viability. It binds to the MED9 submodule in the middle module and anchors the
other subunits of the tail module to the core Mediator (Myers et al., 1999; Li et al.,
1995).
Activators such as Gcn4 and Gal4 bind to subunits MED16 and MED15 (Myers et al.,
1999; Bhoite et al., 2001; Han et al., 1999). Deletion of these subunits abolishes acti-
vated transcription by Gcn4, Gal4 or VP16 in yeast, but not basal transcription (Park
et al., 2000). Recent studies in S. cerevisiae suggest that this module might function
as a separate entity, which can be recruited to promoters independently of the core
Mediator (Zhang et al., 2004; Bjorklund and Gustafsson, 2005). Additional activator
independent functions of the yeast Mediator MED15 (Gal 11) module in PIC forma-
tion and reinitiation were found. Mutations in MED3 and MED16 destabilize PICs
and lead to non-functional scaffold complexes (Reeves and Hahn, 2003). Mutations in
MED3 lead to the partial disruption of the MED15 complex and therfore to defects in
transcription reinitiation. In addition to its role in transcription activation, the Mediator
tail module has a role in transcription repression. All proteins in the tail module (and
some proteins in the head and middle module) have been discovered in screens for
mutations affecting transcriptional regulation, mostly repression and not activation.
1.5.4 The CDK8/CyclinC module of Mediator
A subpopulation of Mediator complexes contain a CDK8/CyclinC module, which con-
sists of CDK8/CyclinC, MED12 and MED13. This module is conserved in eukaryotes
(Samuelsen et al., 2003; Boube et al., 2002), and phosphorylates the CTD at serine 5 of
the heptapeptide repeat (Borggrefe et al., 2002; Hengartner et al., 1998). S. cerevisiae
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Mediator containing this module is implicated in transcription repression (Hengartner
et al., 1998), S. pombe Mediator lacking this module has a stimulatory effect (Spahr
et al., 2003). The holoenzyme complex consisting of Pol II and the Mediator does not
contain the CDK8/CyclinC module (Samuelsen et al., 2003). The human Mediator
complexes NAT and SMCC containing the CDK8/CyclinC module are not capable of
activated transcription (Gu et al., 1999; Sun et al., 1998). There are also reports on pos-
itive effects of the CDK8/CyclinC module on transcription by the recruitment of Gal4
activation domain (Ansari et al., 2002) and the phosphorylation of the gene-specific ac-
tivator Sip4 (Vincent et al., 2001). CDK8/CyclinC phosphorylates TFIID subunits (Liu
et al., 2004) as well as MED2 (Hallberg et al., 2004). Mutation of the MED2 phospho-
rylation site reduces expression levels of certain genes. The CDK8/CyclinC module
promotes ATP dependent dissociation of preinitiation complexes to the scaffold com-
plex (Liu et al., 2004). In addition to its function in transcription, the CDK8/CyclinC
complex plays also a role in cell cycle regulation in human cells. (Ren and Rollins,
2004; Sage, 2004; Akoulitchev et al., 2000). The structure of CyclinC has recently
been solved (Hoeppner et al., 2005) and CDK8 was modeled from the existing struc-
ture of CDK7 (Hoeppner et al., 2005).
1.5.5 MED25, an additional human Mediator subunit
Mediator complexes of higher eukaryotes contain several additional proteins compared
to the yeast Mediator (MED23 to MED30) (Bourbon et al., 2004, Table 2). MED25
(Arc92/ACID1) was identified as a target of the Herpes simplex virus transactivator
VP16 (Mittler et al., 2003; Yang et al., 2004) in human and it has been copurified with
Mediator (Naar et al., 1999). The MED25 protein is conserved in mammals, flies, fish
and chordata and is present in only a subpopulation of human Mediator complexes.
Gst pull-down assays identified Dif and HSF as cellular MED25 interacting activators
in Drosophila (Kim et al., 2004; Kim and Lis, 2005). MED25 associates with the
Mediator through a von Willebrand type A domain which is linked through a proline-
and glutamine-rich linker to its activator interaction domain (ACID). Prostate tumor
overexpressed gene (PTOV-1) is the only gene in the database with sequence homology
to ACID. PTOV-1 contains two ACID copies.
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1.6 Herpes Simplex Virion Protein 16 (VP16), a viral activator of
transcription
Transcriptional activator proteins regulate gene expression in response to environ-
mental changes. Activator proteins have a modular architecture. They generally con-
tain two domains: a DNA-binding domain which recognizes specific sequences and
an activation domain which recruits components of the transcription machinery and
chromatin modifying factors. Because activation domains can act independently of
the DNA-binding domains, artificial chimeras containing a heterologous DNA-binding
domain are often used (Sadowski et al., 1988). One example is the Gal4-VP16 fusion
protein, where a Gal4 DNA-binding domain is fused to the VP16 activation domain.
VP16 contains an activation domain at the C-terminus (residues 411-490), which can
be subdivided into two regions, H1 (residues 411-452) and H2 (residues 453-490). H1
and H2 can activate transcription independently in vivo, and they act synergistically
(Walker et al., 1993). The VP16 activation domain belongs to the group of acidic
activation domains. Initially, acidic activation domains were thought to activate tran-
scription as “acidic blobs”, which contain an amphipathic α-helix with an acidic face
(Sigler, 1988). Later, however, additional motifs were discovered to be critical for ac-
tivation functions. In VP16, hydrophobic phenylalanines are important for activation
(Cress and Triezenberg, 1991; Sullivan et al., 1998).
The H2 region of the activation domain undergoes an induced transition from random
coil to α-helix upon binding to a human TAF (TBP associated factor) (Uesugi et al.,
1997). Formation of an α-helix in the VP16 activation domain is also observed upon
binding to PC4 (Jonker et al., 2005). While α-helix formation was clearly visible
for the C-terminal H2 part of the activation domain, the N-terminal H1 part showed
hardly any secondary structure in this study. Among several other targets within the
transcriptional machinery and chromatin-associated factors, VP16 binds to the mam-
malian Mediator complex via MED25 (Mittler et al., 2003; Yang et al., 2004). VP16
recruits MED25 and Mediator and thereby activates transcription. This interaction
seems to be important in vivo, since the ACID domain of MED25 acts in a dominant
negative way (Mittler et al., 2003; Yang et al., 2004).
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1.7 Aims and scope of this work
High-resolution structural information of Mediator is required in order to gain insights
into the molecular mechanism of this fundamental complex. To obtain X-ray struc-
tures, large amounts of high quality protein samples have to be purified. The modular
structure as well as the low abundance of Mediator within the cell have so far ham-
pered X-ray structure determination of the natively purified complex. Single Mediator
subunits cannot be easily overexpressed in recombinant E. coli systems, mainly due to
the hydrophobic nature of proteins occurring in such large complexes.
The aim of the project was to establish a recombinant E. coli expression system to ana-
lyze pairwise interactions between proteins belonging to the Mediator middle module,
in order to generate subcomplexes suitable for crystallization. A short-term objective
was the crystallization and subsequent structure determination of such subcomplexes.
A longer-term objective was the reconstitution of a recombinant Mediator middle mod-
ule. Such a recombinant complex could then be used for biochemical characterization
and to solve higher resolution structures of the Mediator middle module with and with-
out Pol II. Identification of the subunits contacting the Pol II is an important step in
understanding how Mediator regulates the polymerase. A second aim of the work
was to take first steps towards understanding how activators contact the Mediator. A
previously identified activator interaction domain of the mammalian Mediator subunit
Med25 (Mittler et al., 2003; Yang et al., 2004) was analyzed for its binding to the viral
activator VP16.
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2 Results
2.1 The MED7/MED21 subcomplex: Structure and protein inter-
actions
2.1.1 Subcomplex domain mapping
Individually expressed recombinant Mediator subunits are generally insoluble, ex-
plaining the current lack of Mediator subunit structures. Insolubility apparently results
from a loss of structural integrity when subunits are outside their natural multi-protein
context. To overcome this obstacle, I coexpressed the highly conserved and essen-
tial S. cerevisiae Mediator subunits MED7 and MED21 in E. coli with the use of a
bicistronic vector (Experimental procedures 4.2). Purification by a His tag on Med21
copurified MED7. To probe for flexible regions that my prevent crystallization the
purified MED7/MED21 complex was subjected to partial proteolysis. Chymotrypsin
treatment resulted in the removal of 101 poorly conserved N-terminal residues of
MED7 (Figure 2A). A corresponding variant MED74N (MED7 residues 102-222)
still formed a stable complex with MED21 after coexpression. Sequence alignment
showed a non-conserved C-terminus of MED7 after amino acid 205. A subsequently
prepared variant MED74N4C (residues 102-205) still bound MED21 strongly. This
variant comprises only the highly conserved region of MED7, which shows 59 %
sequence homology between the yeast and human proteins. Except for a short C-
terminal truncation, MED21 remained stable in all proteolysis experiments (Figure
2B). In contrast, individually expressed MED21 was readily cleaved before residues
38 and 76. Therefore, MED21 is protected from degradation upon MED7 binding.
Taken together, iterative proteolysis and truncation of coexpressed and copurified sub-
units allowed us to map a stable subcomplex, and this approach may be used to obtain
potentially crystallizable portions of other multi-protein complexes.
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Figure 2: Partial proteolysis of MED7/MED21 complex: A) Coomassie-stained
SDS-PAGE of a chymotrypsin digest of MED7/MED21 complex. Arrows mark
bands analyzed by Edman sequencing. The resulting N-terminal sequence is given
in one letter code. B) Coomassie-stained SDS-PAGE of a proteinase K digest of
MED7∆N∆C/MED21. The sequenced bands are indicated by arrows. C) Schematic
diagram of the MED7 and MED21 proteins. Blue bars indicate regions of homologous
sequences in different species. Numbers correspond to the percentage of homology
between yeast and human. Proteolytic cleavage sites are indicated above the schemes
with black (sequenced) or grey arrows (estimated from SDS-PAGE). Red crosses indi-
cate the protection of the cleavage site by the interaction partner.
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2.1.2 Purification of crystallizable MED7/MED21 variants
The exact protocols for purification of the different variants of the MED7/MED21
complex are described in Experimental Procedures (4.1.5). As the protein complex
tends to form aggregates at a pH below 7.5, all steps throughout the purification were
carried out at pH 8.5. First protein was enriched either by Ni-NTA affinity purification
(MED7∆N∆C/MED21) or by ammonium sulfate precipitation (MED7∆N∆C/MED21∆C).
Ammonium sulfate precipitation is a very powerful purification step since the proteins
of the Mediator middle module precipitate below 35 % saturated ammonium sulfate,
a concentration in which most E.coli proteins are still soluble. The pellet can be col-
lected, proteins redissolved and further purified by anion exchange (Figure 3A) and
gelfiltration chromatography (Figure 3B). Anion exchange chromatography is impor-
tant to separate the MED7/MED21 complex from excess MED21, which does not bind
the column. The gelfiltration step is not needed for purification of the complex but is
used to remove eventual aggregates and ensure complete buffer exchange to the buffer
used for crystallization. The quality of the protein preparation is very high (Figure 3B)
and the complex is easy to handle. Aliquots of 50 µl could be flash frozen in liquid
nitrogen and stored at -80◦ C for later use.
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Figure 3: Purification of MED7d∆N∆C/MED21∆C: A) MonoQ anion exchange
chromatography of MED7∆N∆C/MED21∆C. Blue: absorption at 280 nm. Red:
conductivity. SDS-PAGE analysis of the peak fraction is shown next to the peak.
Proteins and standards are indicated. B) Superose 6 gelfiltration chromatography of
MED7∆N∆C/MED21∆C. The absorption at 280 nm is measured. SDS-PAGE anal-
ysis of the peak fraction is shown next to the peak.
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2.1.3 Crystallization of the MED7/MED21 heterodimer
Preparations of the MED74N4C/MED21 subcomplex were monodisperse and homo-
geneous according to dynamic light scattering and size exclusion chromatography.
Crystallization trials using commercial Hampton screens were set up with the hanging
drop vapor diffusion method. Microcrystals were obtained and could be refined by
varying salt and ethanol concentrations as well as screening various additives. These
screens lead to the observation that addition of β-mercaptoethanol improves crystal
size and quality. The final crystallization condition was: 0.8-1.1 M NaCl, 10-15 %
ethanol, 0-3 % PEG 6000, 10 mM β- mercaptoethanol, 10 mM EDTA. Crystals grew
to a maximum size of 0.6 x 0.3 x 0.3 mm and comprise two heterodimers per asym-
metric unit (space group C2221) (Figure 4). The crystals were very sensitive to cryo-
cooling and a slow cryo-protocol using microdyalisis buttons had to be established.
Despite the large size of the crystals, diffraction extended only to 3.3 Å in favorable
cases.
Figure 4: Crystals of the MED74N4C/MED21His complex obtained in the Hampton
screen 2 condition 8 (1.5M NaCl, 10% ethanol, left) and in the refined condition (0.8
M NaCl, 10 % ethanol, 3 % PEG 6000, 10 mM β-mercaptoethanol, 10mM EDTA,
right). This crystal grew to a maximal size of 50x 50x 150µM.
To increase the resolution limit of the crystals, I truncated eight non-conserved amino
acid residues from the MED21 C-terminus (variant MED214C, residues 1-132), which
where unstable in protease digest experiments (Figure 2B). The resulting complex
MED74N4C/MED214C crystallized in additional conditions, not containing ethanol
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(see Experimental procedures 4.2.5, Figure 5). Crystals adopted space group P4322.
These crystals were slightly more stable, and could be used for structure determination.
Figure 5: Crystals of the MED74N4C/MED214C complex obtained in the Hampton
screen and in the refined condition (Experimental Procedures 12).
2.1.4 Methionine mutations enhance the anomalous signal
Initial attempts of structure determination by multiple anomalous dispersion (MAD)
were done using selenomethionine substituted crystals of MED7∆N∆C/MED21His.
Data to 3.8 Å resolution were obtained. The anomalous signal of the crystal containing
seven methionines per heterodimer (including the N-termini) was strong enough to find
three selenium peaks and obtain initial phases. However the quality of these phases
was very poor and the resulting electron density map could not be used for model
building. To increase the anomalous signal and thus obtain better phasing power I
replaced three leucines in MED21 by methionines (L5M, L119M, L125M). The po-
sitions for the mutations were chosen such that they lay in conserved regions with
predicted secondary structure and could serve as sequence markers during model buil-
ding. MAD data to 3.6 Å resolution was obtained from the resulting crystals and could
be used for phasing (Table 3).
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Crystal SeMet MAD Native Native
MED7∆N∆C/ MED7∆N∆C/ MED7∆N∆C/
MED21∆C1 MED21∆C1 MED21
Data collection
Space group P4322 P4322 C2221
a (Å) 85.6 85.7 121.5
b (Å) 85.6 85.7 128.9
c (Å) 185.2 183.0 170.2
Wavelength (Å) 0.9795 peak 0.979
inflection
0.9686
remote
0.9795 1.0749
Resolution range 20-3.6 (3.73-
3.6)2
20-3.6 (3.73-
3.6)
20-3.6 (3.73-
3.6)
50-3.0 (3.11-
3.0)
50-3.3 (3.42-
3.3)
Completeness (%) 100 (100) 100 (100) 100 (100) 98.6 (100) 99.6 (99.5)
Unique reflections 8517 8517 8517 14180 20641
Redundancy 6.9 6.5 6.7 5.4 4.8
Rsym (%) 8.3 (21.0) 8.7 (32.0) 7.8 (26.0) 6.5 (26.2) 5.8 (36.2)
<I/σ> 7.6 6.4 6.8 8.9 10.4
f’3 -8.0 -9.8 -3.8
f”3 4.9 2.5 3.7
Table 3: Diffraction data
1The triple point mutant L5M/L119M/L125M of MED21 was used.
2The numbers in parenthesis correspond to the highest resolution shell.
3The values for f’ and f” where obtained from a fluorescence scan of the derivative
crystals.
2.1.5 Structure determination of the MED7/MED21 heterodimer
The structure was solved with MAD data from a selenomethionine-substituted crys-
tal of MED7∆N∆C/MED21∆C containing the mutations, and was refined to a free
R-factor of 28.9 % against native diffraction data extending to 3.0 Å resolution (Experi-
mental procedures, Table 4). I used the refined structure of the MED7∆N∆C/MED21∆C
heterodimer to solve the structure in the initial crystal form (space group C2221,
MED7∆N∆C/MED21) by molecular replacement. I refined this structure to a free
R-factor of 31.4 % with data extending to 3.3 Å resolution (Table 4).
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Crystal Native Native
MED7∆N∆C/MED21∆C1 MED7∆N∆C/MED21
Number of residues 209 428
Non-hydrogen
atoms
1737 3549
RMSD bonds (Å) 0.008 0.009
RMSD angles (◦) 1.164 1.37
Ramachandran plot2
(core/allowed/additionally
allowed)
94.3/5.7/0 87.9/11.8/0.3
Rcryst (%) 25.7 27.9
Rfree (%) 28.9 31.4
Table 4: Refinement statistics
1The triple point mutant L5M/L119M/L125M of MED21 was used.
2PROCHECK (56).
2.1.6 The MED7/MED21 structure
Elongated two domain structure
MED7 and MED21 form a very elongated heterodimer of purely helical structure (Fig-
ure 6). The heterodimer extends over 110 Å, corresponding to one third of the Me-
diator length (Davis et al., 2002), and amounting almost to the diameter of Pol II
(Cramer et al., 2001) (Figure 6). This elongated shape is consistent with an unusually
short retention in size exclusion chromatography (Figure 7). The retention of the
MED7/MED21 species lies between that of the standard proteins aldolase (157 kDa)
and catalase (230 kDa), and may be explained by formation of tetramers (dimers of het-
erodimers). Two different types of tetramers are observed in the crystal, which show a
computed (Garcia De La Torre et al., 2000) Stokes radius of 42-44 Å. This is in good
agreement with the Stokes radii for aldolase and catalase (47 Å and 49 Å, respectively),
whereas the Stokes radius of the MED7/MED21 heterodimer is only 31 Å. Thus the
complex apparently forms stable tetramers in solution. Deletion of the C-terminus of
MED21 (MED21 1-102) results in longer retention on size exclusion chromatography,
indicating that the C-termini are responsible for dimerization. The C-termini are also
involved in the formation of one of the heterotetramers in the crystals. Static light scat-
tering also indicates a molecular weight of about 60kDa and a hydrodynamic radius of
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49 Å, consistent with a heterotetramer. MED7 and MED21 show no sequence similar-
ity, but they have the same structural organization, comprising three extended helices.
MED7 and MED21 tightly pack against each other, forming a heterodimer with two
domains. A 4-helix bundle domain is formed by the two N-terminal α-helices of each
subunit, and the C-terminal α-helices of the two subunits form a long coiled-coil pro-
trusion (Figure 6). A “hinge” region connects the bundle domain to the coiled-coil
protrusion.
Figure 6: MED7/MED21 (Med7/Srb7) structure: Two views of a ribbon model of the
MED7/MED21 complex, related by a 90◦ rotation around the vertical axis. MED7 is
in orange, MED21 in purple. Figure prepared with DINO (http://www.dino3d.org).
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Figure 7: Size exclusion chromatography: The MED7/MED21 complex shows an
unusually short retention in size exclusion chromatography. The elution profile of
MED7/MED21 on a Superose-6 column (Amersham) is overlaid to those of standard
proteins (thyroglobulin, ferritin, catalase, and aldolase). Protein elution was monitored
by UV absorption at 280 nm. For details see Experimental procedures.
A conserved flexible hinge Comparison of the MED7/MED21 structure in the two
crystal forms reveals that the coiled-coil protrusion can undergo a hinge movement
with respect to the bundle domain, giving rise to a 10 Å-displacement of the C-terminal
end of the protrusion (Figure 8). This repositioning of the protrusion is accommodated
by a slight conformational adjustment in the hinge region. Thus the MED7/MED21
heterodimer has an intrinsic flexibility that allows for a relative repositioning of the two
domains. This flexibility is not due to the short C-terminal truncation of MED21 in the
C2221 crystal form, since the two chemically identical heterodimers in the asymmetric
unit also show two different conformations indicating the same hinge motion, and since
the truncated residues are not involved in packing interactions in the C2221 crystal
form. The high sequence conservation of amino acid residues in the hinge region
of MED7 and MED21 (Figure 9A) strongly suggests that the observed flexibility is
functionally significant. A hinge movement is also predicted by molecular dynamics
simulation with the Dynamite server (http://dynamite.biop.ox.ac.uk/dynamite).
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Figure 8: MED7/MED21 hinge. Structures in two different crystal forms have been
superimposed with their bundle domains, resulting in a 10 Å difference at the end of
the coiled-coil in the C2221 crystal form (color) compared to the P4322 crystal form
(grey).
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MED7-MED21 interaction MED7 and MED21 form a continuous hydrophobic in-
terface, which explains why subunits that are individually expressed in E. coli are
structurally unstable and either poorly soluble or easily degraded. The hydrophobic
residues in the MED7-MED21 interface along the coiled-coil protrusion are mostly
conserved throughout eukaryotes and show a spacing typical for coiled coils (MED7
residues L175, L178, L182, I189, I192; MED21 residues I94, L97, L101, V104, A111)
(Figures 9A, B). In MED7, the regular spacing of hydrophobic residues is discontinued
only at residue K185. The regular pattern in MED21 is similar, except residues Q90,
K108, and K115, which however also participate in fold-stabilizing interactions. The
conserved MED21 residue Q90 forms hydrogen bonds with E172 and R171 of MED7,
and may contribute to the specificity of the heterodimeric interaction. Given the high
degree of sequence conservation of the crystallized regions, the MED7/MED21 struc-
ture must essentially be the same in all species. This conservation in structure explains
why a chimeric MED21 protein consisting of the two human N-terminal helices (cor-
responding to yeast residues 1-81) and the yeast C-terminal helix (residues 82-140) is
functional in vivo (Chao et al., 1996), and why truncation of the MED21-interacting
region of MED7 is lethal in C. elegans (Kwon et al., 2001).
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Figure 9: (A) Sequence alignments of MED7 and MED21 from S. cerevisiae (S.c.),
D. melanogaster (D.m.), H. sapiens (H.s.), and S. pombe (S.p.). Helical regions are
shown above the alignments as cylinders. Residues are highlighted in dark green, light
green, and yellow, according to decreasing degree of conservation. Residues in the
structural core are marked with black open circles. Core residues that are addition-
ally involved in crystal contacts are marked with a black dot. Red dots and squares
indicate residues involved in crystal contacts of the bundle and coiled-coil domains,
respectively. Filled triangles indicate protease cleavage sites determined by Edman se-
quencing, outlined triangles indicate approximate C-terminal protease cleavage sites.
(B) MED7-MED21 interactions. On the left, the Connelly surface of MED21 (probe
radius 1.2 Å) is shown together with a ribbon model of MED7. The view is as in
Figure 6. On the right, the Connelly surface of MED21 (probe radius 1.2 Å) is shown
together with a ribbon model of MED7. The two views are related by a 180◦ rotation
around a vertical axis. Conserved residues are mapped on the surfaces of one sub-
unit and are colored according to A. (C) Heterotetramerization in the crystal mediated
by interaction of the open ends of the C-terminal coiled-coils. Residues involved in
crystal contacts are marked in A. (D) Heterotetramerization in the crystal, mediated by
interaction between the bundle domains.
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A unique leucine zipper The coiled-coil protrusion resembles a canonical leucine
zipper as it occurs in transcription factors like c-Jun (Junius et al., 1996) or Gcn4
(Keller et al., 1995; Holm and Sander, 1995). The two helices of the coiled-coil
separate at their C-terminal end. The inner side of this open end of the zipper is
conserved and hydrophobic (MED21 residues L118, V122, I126, and F129; MED7
residues L203 and V199), and thus chemically different from the corresponding re-
gion in leucine zipper-containing transcription factors, which show exposed polar or
charged residues for DNA binding in this region. Instead of binding DNA, the open
end of the MED7/MED21 coiled-coil may interact with other Mediator subunits. In
both crystal forms, two heterodimers pack against each other via their coiled-coil ends
(FIG. 9C), indicating that the open end of the coiled-coil may allow for protein inter-
actions.
2.1.7 Conserved interactions of the MED7/MED21 heterodimer within the Me-
diator middle module
To map direct protein-protein interactions of the MED7/MED21 heterodimer with
other subunits in the Mediator middle module, I tested for copurification of subunits
after their coexpression in E. coli (Figure 10A). Such copurification can successfully
map strong and specific direct protein-protein interactions, as demonstrated in the
structure determination of the MED7/MED21 complex. The copurification assay is
very stringent, since many different non-specific competitor proteins are present in
the E. coli lysate, since the stoichiometry of the complexes can be estimated with
Coomassie-stained gels, and since the protein-protein complexes must persist over se-
veral copurification steps, even when elevated salt concentrations of 600 mM NaCl are
used. E. coli was cotransformed with two plasmids, a bicistronic plasmid expressing
the MED7/MED21 heterodimer, and a second plasmid with different antibiotic resis-
tance, expressing a third subunit. I found that the MED7/MED21 heterodimer strongly
binds MED10 and MED4, which show 39 % and 33 % sequence homology between
yeast and human, respectively, and belong to the most conserved core Mediator sub-
units together with MED7, MED21, MED31 (Soh1) and MED6 (Figure 10A). In con-
trast, the other two subunits of the middle module, MED1 or MED9 do not copurify
with the MED7/MED21 complex. To test if MED21 alone is sufficient for the interac-
tions with MED10 or MED4, I constructed bicistronic vectors for coexpression. These
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experiments revealed that MED21 alone is capable to bind MED10 or MED4 (Figure
10B).
Figure 10: Protein-protein interactions of the MED7/MED21 complex. (A) Copurifi-
cations of MED7∆N∆C/MED21 heterodimer with either MED10His or MED4His.
(B) Copurification of MED21His with MED7, MED10 and MED4. (C) Copurifica-
tions of MED4His with GstMED7 and MED9. Gels were stained with Coomassie
Blue.
2.1.8 MED4 and MED9
Urea dissociation experiments of yeast Mediator middle module subunits by Han et
al. (Han et al., 2001) identified two stable subcomplexes within the Mediator middle
module. One consisting of MED7/MED10/MED21 was already reconstituted earlier
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in this study. The three other subunits of the middle module, MED1, MED4 and
MED9 also form a stable subcomplex. Coexpression of MED4His and MED9 leads
to massive overexpression of both proteins. Subsequent purification of MED4 by His
affinity chromatography copurifies MED9 (Figure 10C). Coexpression of a plasmid
encoding for the genes of MED4 and MED9 with a plasmid encoding for MED1His did
not allow for the copurification of MED4/MED9. MED4 also interacts with MED7.
Purification of MED4 and MED7 using a His tag on MED4 leads to the copurification
of both proteins. In a second purification step using an N-terminal Gst tag on MED7
a stoichiometric MED4/MED7 complex is purified (Figure 10C). This copurification
is not due to the Gst-tag since MED4 also copurifies MED7 if Gst is not present. It
is interesting to note that the expression of GstMED7 is only possible in the presence
of MED4. Together with the interaction of MED4 and MED21 shown in 2.1.7 this
establishes the interaction between the two subcomplexes of the middle module.
2.1.9 MED6 bridges two Mediator modules
I could additionally demonstrate that the MED7/MED21 heterodimer binds directly
to MED6, which shows 34 % sequence homology between yeast and human (Figure
11A). While MED7, MED21, MED4 and MED10 are all subunits of the middle mo-
dule, MED6 is an integral part of the head module (Lee and Kim, 1998), suggesting
that MED6 bridges these two modules. To test if MED6 binds directly to MED17
(Srb4), the architectural subunit of the head module (Koh et al., 1998), I tagged MED6
with a C-terminal hexahistidine tag (His), fused MED17 to a N-terminal Gst tag (Gst),
and coexpressed the two subunits from a bicistronic vector. I could copurify the two
subunits in two subsequent affinity chromatography steps, using a Ni-NTA and a glu-
tathione column (Figure 11A, B). Successful purification of the complex was indepen-
dent of the order of the affinity columns. The weakly conserved N-terminal part of
MED17, and the non-conserved C-terminal part of MED6, are not required for bind-
ing since truncated variants of MED17 (residues 241-688) and MED6 (residues 1-214)
were sufficient for the interaction. These results are consistent with a functional inter-
action between MED17 and MED6 observed previously (Lee and Kim, 1998). The
results are further consistent with a very recent study of Mediator subunit interactions
by yeast two-hybrid analysis (Guglielmi et al., 2004). In conclusion, MED6 physically
bridges between the two Mediator core modules, interacting with MED17 in the head
module and with the MED7/MED21 heterodimer in the middle module.
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Figure 11: (A) Copurification of MED6His with MED7∆N∆C/MED21 or
GstMED17∆N. A schematic presentation of the purification procedure is shown
above the gels. Gels were stained with Coomassie Blue. (B) Western blot of the
GstMED17∆N/MED6His purification. The binding of MED6 to MED17 is not due
to the presence of the Gst tag since a purification using Gst only does not yield MED6
(fourth lane).
2.1.10 MED31: an integral part of the middle module
While this study was underway, an additional yeast Mediator subunit, MED31 (Soh1)
was identified (Guglielmi et al., 2004; Linder and Gustafsson, 2004). MED31 has been
known to be part of murine Mediator complexes. It has very strong homology of 50
% between yeast and human which makes it to the most conserved Mediator subunit
except for CDK8/CyclinC (Linder and Gustafsson, 2004). Yet no purification of yeast
Mediator has found MED31 associated to it before.
According to yeast two hybrid screens performed by Guglielmi et al. this additional
subunit interacts with MED10 and MED21 and it therefore seems to be an integral part
of the middle module (Guglielmi et al., 2004). To test for direct protein protein interac-
tions, I coexpressed MED31 together with subunits of the middle module and MED6
in E. coli and pulled on the proteins by a His tag on one of the subunits (Figure 12A).
The results indicate an interaction of MED31 with either MED4, MED7, MED10 or
MED21, but not with MED6. As a negative control overexpressed MED31 was incu-
bated with Ni-NTA beads. I could therefore confirm that MED31 is an integral part of
the middle module in yeast Mediator.
Coexpression and purification of MED10His or MED7∆N∆C/MED21His with MED31
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leads to copurification of MED31. However, the complexes are not stable during pu-
rification and tend to aggregate. Limited proteolysis of purified MED10His/MED31
using chymotrypsin, trypsin or proteinase K reveals that MED31 is very stable (Fig-
ure 12B). MED10 in contrast is degraded after 1 minute of incubation with any of
the proteases used. Having found a very stable Mediator protein I expressed, purified
and crystallized MED31 alone. MED31 can be expressed and purified in very small
amounts. Crystals could be obtained in initial crystallization setups in condition 7 of
the Nextal classic screen (100 mM Na citrate pH 5.6, 20 % isopropanol, 20 % PEG
4000). These crystal grew at a maximal size of about 20 x 20 x 10 µm. However, they
did not diffract on a home source and were not easily reproducible.
Figure 12: MED31 interacts with several subunits of the middle module: (A) Pull
down of MED31 with MED4, MED6, MED7, MED10 and MED21 with the use of
a His tag on these proteins. The names of the Proteins are indicated on the left, the
molecular weight (kDa) on the right side of the gel. (B) Limited proteolysis of copu-
rified MED10/MED31 complex by chymotrypsin. Proteins and the molecular weight
(kDa) are indicated. Polyacrylamide gels are stained with Coomassie blue.
2.1.11 Reconstitution of larger subcomplexes of the Mediator middle module
Given the central role of the MED7∆N∆C/MED21 complex within the Mediator
middle module it could serve as a scaffold for crystallization and structure determi-
nation of larger complexes. Taking advantage of the interaction partners determined
by the copurification assay, I reconstituted trimeric subunit complexes containing the
MED7∆N∆C/MED21 heterodimer together with either MED4 or MED10 as well as
a tetrameric complex containing MED4 and MED9.
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Complexes of MED7∆N∆C/MED10/MED21 or MED4/MED7∆N∆C/MED21 were
purified with the use of the His tags on MED4 or MED10. Nickel affinity and anion
exchange chromatography resulted in stoichiometric MED7∆N∆C/MED10/MED21
complex, which elutes as one peak from a size exclusion column.
MED4/MED7∆N∆C/MED21 was not purified as a stoichiometric complex by Ni
affinity and anion exchange chromatography. An excess of monomeric MED4 was
removed from the complex by two subsequent rounds of size exclusion chromatog-
raphy. A complex of MED4/MED7∆N∆C/MED9/MED21 was purified in the same
way. All purified complexes were used for crystallization trials.
Analytical size exclusion chromatography shows an unexpected short retention volume
of the trimeric complexes, similar to that of the MED7/MED21 heterodimer (Figure
13). MED10 does not contribute much to the overall shape and its retention volume is
only slightly larger than that of MED7∆N∆C/MED21, indicating that it may form a
stable heterohexamer (dimer of trimers). The complex containing MED4 has a reten-
tion time which lies between that of the standard proteins ferritin (440 kDa) and cata-
lase (232 kDa). A complex containing MED4 seems to have an even more pronounced
elongated shape than the MED7∆N∆C/ MED21 heterodimer. Inclusion of MED9 into
a complex containing MED4/MED7∆N∆C/MED9/MED21 leads to a retention time
slightly shorter than that of ferritin. This corresponds to a even more elongated shape.
Taken together this indicates that the dimerization seen in the MED7∆N∆C/MED21
complex persists also in complexes containing additional subunits. Alternatively, that
one of the heterodimers is replace by the new subunits which still have very elongated
shapes.
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Figure 13: Size exclusion chromatography of subcomplexes of the Mediator mid-
dle module: The complexes containing MED7/MED21 and MED4, MED4/MED9 or
MED10 show unusually short retention in size exclusion chromatography. The elu-
tion profiles of the complexes on a Superose 6 column (Amersham) are overlaid. The
elution of the standard proteins thyroglobulin (660 kDa), ferritin (440 kDa), catalase
(232 kDa), and aldolase 158 kDa) is indicated by arrows below the chromatogram.
Protein elution was monitored by UV absorption at 280 nm. For details see Experi-
mental procedures.
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Crystallization of MED7∆N∆C/MED10/MED21 and MED4/MED7∆N∆C/MED21
The MED7∆N∆C/MED10/MED21 complex crystallized under the same conditions
as the MED7∆N∆C/MED21 complex using the hanging drop vapor diffusion method.
The presence of MED10 was confirmed by mass spectrometry of washed and dissolved
crystals. The crystals were frozen as described for the MED7/MED21 complex. Af-
ter complete exchange of the crystallization to the cryo-solution the crystals where
soaked with individually purified MED10. Presence of monomeric protein should
ensure complete occupancy of MED10 in the crystal. MED4/MED7∆N∆C/MED21
crystallized with lower concentrations of sodium chloride as well as in conditions con-
taining ammonium acetate. The complex of MED4/MED7∆N∆C/MED9/MED21 did
not crystallize. In order to analyze the crystals, they were washed 4 times with the
mother solution and dissolved. SDS PAGE analysis of crystals containing MED4 in
addition to MED7∆N∆C/MED21, confirmed the presence of all three prmonomeri-
coteins. Crystals were frozen in presence of monomeric MED4, in the same way as
the MED7/MED10/MED21 complex described above.
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Figure 14: Refined crystals of MED4/MED7∆N∆C/MED21 and
MED7∆N∆C/MED10/MED21. The crystallization conditions are listed in Ex-
perimental Procedures 12. These crystals were used for structure determination.
Structure determination MED7∆N∆C/MED10/MED21 and MED4/MED7∆N∆C/MED21
Despite the different crystallization conditions diffraction analysis for both trimeric
complexes revealed unit cells having the same dimensions as the MED7∆N∆C/MED21
crystals. I solved the structures by molecular replacement in the case of MED7∆N∆C/
MED10/MED21, using the refined MED7∆N∆C/MED21 structure as a search model.
For MED4/MED7∆N∆C/MED21 The structure was solved by SAD phasing using a
selenomethionine-substituted crystal diffracting to 3.0 Å resolution. The structure of
MED4/MED7∆N∆C/MED21 was refined to a free R-factor of 31.4 % with data ex-
tending to 3.0 Å resolution.
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Electron densities of MED7∆N∆C/MED10/MED21 and MED4/MED7∆N∆C/ MED21
crystals did not reveal the additional subunits. Despite careful inspection of the elec-
tron density, there is no additional electron density corresponding to the presence of
the third subunit. This came as a surprise since both trimeric complexes seem very sta-
ble during purification, and since analysis of the crystal contents revealed the presence
of the additional subunits. Structure determination by selenomethionine labeling and
de novo SAD phasing for the MED4/MED7∆N∆C/MED21 complex prevents model
bias, repositioning of the model in the electron density and refinement confirm the re-
sults obtained during the structure determination of MED7/MED21 complex, but do
not show any additional electron density. The reason for this could be, that there are
only peptide interactions between the MED7/MED21 complex and MED4 or MED10.
These interactions might be mediated through less stable regions of the MED7/MED21
complex like the loop between helix α1 and helix α2 of MED21. MED4 or MED10
might still be there in the crystal but not visible because MED4 and MED10 are not
involved in crystal contacts and therfore not bound in a stable conformation. In agree-
ment with this scenario, the presence of MED10 in the MED7/MED21 complex sta-
bilizes the MED7/MED21 complex during protease digests. In the same experiment
MED10 is not stable, indicating that large parts of the protein are not folded. To obtain
the structure of larger complexes of the middle module, additional subunits should be
included, which could stabilize MED4 and MED10 and reduce their flexibility.
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2.2 Reconstitution of a hexameric Mediator middle module that
binds RNA polymerase II
Our results show that it is possible to reconstitute subcomplexes of the yeast Mediator
middle module by coexpression in E. coli. Coexpression can lead to soluble protein
complexes. The expressed proteins fold and assemble into their native complexes. To
achieve the goal of the reconstitution of a homogeneous Mediator middle module I
chose a strategy that combines coexpression of soluble subcomplexes and assembly
of these complexes to form a complete middle module. Based on my coexpression
studies and the urea washes done by Han et al. (Han et al., 2001), I chose to coexpress
MED7, MED10, MED21 and MED31 together. MED7, MED10 and MED21 are
expressed from one tricistronic plasmid and a different plasmid harboring MED31His
is cotransformed. After purification the heterotetrameric complex can be assembled
with separately purified MED4/MED9 to form the middle module.
2.2.1 Purification of a tetrameric MED7/MED10/MED21/MED31 Mediator mid-
dle module complex:
Coexpression of MED7/MED10/MED21/MED31 works very well. To selectively
purify a stoichiometric complex, versions with a Histidine affinity tag on MED10,
MED21 or MED31 were tested. Affinity purification by MED10 or MED21 lead to
aggregates of incomplete subcomplexes. However, the tetrameric complex can be puri-
fied by a his tag on MED31. A surplus of MED31 can be removed on the Ni column,
if bound protein is eluted with a stepwise imidazole gradient. The elution at 70 mM
imidazole contained MED7/MED10/ MED21/MED31His. Higher concentrations of
imidazole removed residual MED31 from the column, but no stoichiometric com-
plex. Further purification by anion exchange chromatography resulted in two peaks
(Figure 15A). Only one contained pure MED7/MED10/MED21/ MED31 as is shown
by SDS-PAGE analysis. Separation of the sample by gelfiltration results in one sin-
gle peak, indicating pure and homogenous MED7/MED10/MED21/MED31 complex
(Figure 15B).
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Figure 15: Purification of MED7/MED10/MED21/MED31: (A) Chro-
matogram of the MonoQ anion exchange chromatography of affinity purified
MED7/MED10/MED21/MED31. (B) Superose 6 gelfiltration chromatography of the
main peak from (A). The absorption at 280 nm is measured to detect protein elution
(blue, (A and B)) as well as the conductivity of the elution buffer to follow the salt
gradient (red) in (A). SDS-PAGE analysis of the peak fractions is shown next to the
corresponding peaks. The names of the proteins as well as the molecular weight (kDa)
are given.
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2.2.2 Assembly of the hexameric Mediator middle module consisting of
MED4/MED7/MED9/MED10/MED21/MED31
For the reconstitution of the six-subunit middle module, MED4 and MED9 were cop-
urified as a stoichiometric complex by ammonium sulfate precipitation (Experimen-
tal procedures 4.2.3). The two complexes of MED4/MED9 and Ni affinity purified
MED7/MED10/MED21/MED31His (see 2.2.1) were then mixed with a 1.3 fold ex-
cess of MED4/MED9. The mixture was assembled by incubation for 1 h at room
temperature. The assembled middle module was further purified by anion exchange
chromatography. Hexameric middle module elutes at higher salt concentrations from
the MonoQ than the tetrameric complex. Therefore free tetrameric complexes are
removed (Figure 16A). The excess of MED4/MED9 is removed by a subsequent Su-
perose 6 gelfiltration column (Figure 16B, C). The main peak contains the six proteins
in stoichiometric amounts, as estimated from the intensity of the Coomassie Blue-
stained bands (Figure 16C). Repeated separation of the main peak on a Superose 6
gelfiltration column reveals one single peak (Figure 16B, D). The retention volume
corresponds to a 500 kDa protein complex, which is much bigger than the theoretical
molecular weight of 138 kDa. This is probably due to an unusual elongated shape
of the complex as was observed for the MED7/MED21 structure. A very elongated
structure is also expected from EM data (Asturias et al., 1999). The presence of all
proteins was verified by masspectrometry and Edman sequencing.
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Figure 16: Purification of MED4/MED7/MED9/MED10/MED21/MED31: (A) Chro-
matogram of the MonoQ anion exchange chromatography of the assembled complex.
Complexes containing MED4/MED9 elute later during the salt gradient than tetrameric
complexes. (B) Separation of surplus MED4/MED9 from the hexameric complex (left)
by gelfiltration chromatography. Repeated gelfiltration of the hexameric complex re-
sults in one single peak (right). The absorption at 280 nm is measured to detect protein
elution (blue, (A and B)) as well as the conductivity of the elution buffer to follow the
salt gradient (red) in (A). (C) Coomassie stained SDS Page analysis of the Superose 6
runs shown in (B) Proteins and molecular weight standards are indicated.47
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The resulting complex was subjected to partial proteolysis with trypsin and chymo-
trypsin. The slow degradation revealed a complex which is stable for at least 10 min-
utes. This is longer than observed for most subcomplexes. Appearing fragments were
identified by Edman sequencing and an overview of identified domains can be seen in
Figure 17C and Table 5.
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Figure 17: Partial proteolysis of the Mediator middle module: (A) Coomassie-stained
SDS PAGE of a chymotrypsin digest of the hexameric middle module complex. Num-
bers correspond to bands cut and sequenced by Edman sequencing. Corresponding
sequences are found in table 5. (B) Coomassie stained SDS-PAGE of a trypsin digest
of the hexameric middle module complex. Proteins and Molecular weight are indi-
cated (kDa). The time course of the digests are depicted above the gels. (C) Schematic
diagram of the middle module proteins. Grey bars indicate regions of homologous
sequences in different species. Numbers correspond to the percentage of homology
between yeast and human according to the alignments of MED4, MED10 and MED31
published by Boube et al. (Boube et al., 2002). Proteolytic cleavage sites are indicated
above the schemes in black (sequenced) and grey (estimated from SDS-PAGE). Red
crosses indicate protection of the site by interaction partners within the middle module
compared to th stability of the MED21 alone or MED9 in complex with MED4 only.
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Fragment Sequence Protein Assignment (AA
residues)
Molecular weight
(kDa)
1 MNLQN MED9 1 to 150 17.4
TKIPP MED4 165 to 284 13.4
2 TDRLT MED21 2 to 140 16.1
SMGHI MED4 17 to 164 17.6
3 not identified
4 KKSTENE MED7 102 to 222 14.3
ASNDPGN MED7 2 to 101 11.3
5 ASNDP MED7 2 to 83 9.2
6 KLNVR MED10 62 to 157 11.1
MNLQN MED9 1 to 71 8.0
7 IEDGR MED10 87 to 157 8.3
ASMNG MED10 1 to 61 6.8
8 SLHQI MED9 72 to 124 5.9
Table 5: Partial proteolysis of the Mediator middle module: identified fragments of the
chymotrypsin digest. The numbers correspond to the fragments identified in Figure 17.
The MED7∆N/MED21 complex which was stable during previous limited proteolysis
experiments, is also stable in the middle module complex as expected. The previously
unstable N-terminal domain of MED7 however, is protected by additional interactions
(Bands 4 and 5; Figure 17) and becomes stable in the complex. Therefore MED7
consists of two domains connected by a protease-sensitive loop. MED10 behaves sim-
ilarly, having a highly protease sensitive N-terminus and a C-terminal domain. The
protection of the C-terminal domain is only dependent on MED7∆N/MED21, as lim-
ited proteolysis of MED7∆N/MED10/MED21 gives similar results. MED31 consists
of only one highly conserved domain (70 % between yeast and human, Figure 17C).
This domain is stable in all proteolysis experiments done, except for the his tag. The
extreme N-terminus of MED31 is required for the stability since N-terminal trunca-
tions lead to largely insoluble protein. MED31 is the only protein of the middle module
which does not need interaction partners for its folding and stability. Proteolysis only
reveals two fragments of MED4. Fragment 2 (Table 5; Figure 17) starts close to the
N-terminus of the protein and is similar to fragments obtained in other experiments.
Fragment 1 is a C-terminal 13.4 kDa fragment according to N-terminal sequencing. It
runs at the position of a 21 kDa protein standard. This strange behavior possibly stems
from the many negative charges the domain carries (25 % negatively charged D, E; the-
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oretical pI 4.26). A similar behavior is seen for the VP16 activation domain: a strongly
charged 7.5 kDa polypeptide (28 % negatively charged D, E, theoretical pI 3.46) which
runs at the size of the 21 kDa protein standard (Donaldson and Capone, 1992). These
proteolysis results reveal two domains of MED4, both are stable. The C-terminus of
MED4 strengthens its interaction with MED21 since truncations of MED4 (residues 1
to 208, 1 to 244 ) still interact with MED21 but the two proteins are separated by anion
exchange chromatography.
Only the C-terminal region of MED9 is conserved from yeast to human (Appendix).
However, only the N-terminal part stays intact during proteolysis. Nevertheless the
extreme C-terminus of MED9 is needed for stability of the protein since a C-terminal
truncation (residues 1 to 134) leads to largely insoluble protein (not shown). The
instability of MED4 and MED9 compared to the rest of the middle module might be
due to the missing MED1 subunit. The three subunits (MED1, MED4 and MED9)
form the link to the tail module of the yeast Mediator (Kang et al., 2001; Guglielmi
et al., 2004).
The proteolysis revealed a middle module complex that is stable for at least 10 min
when treated with chymotrypsin and trypsin. There are no large unstructured regions,
indicating a correctly folded middle module complex. None of the individual proteins
MED4, MED10, MED7/MED21, MED4/MED9, except MED31 are stable for this
time. Taken together a stable six-subunit middle module complex can be obtained in
amounts, purity and homogeneity that are suitable for structure determination experi-
ments.
51
2.2 Reconstitution of a hexameric Mediator middle module 2 RESULTS
2.2.3 The Mediator middle module binds Pol II
The Pol II/Mediator middle module complex formed by the 12-subunit Pol II and the
six-subunit Mediator middle module was reconstituted using the following approach:
endogenous 10 subunit Pol II, the additional recombinant polymerase heterodimer
Rbp4/Rbp7 and the recombinant Mediator middle module were mixed in a 1:5:3 molar
ratio. The mixture was incubated at 20◦ C for 1 h and then applied to a Superose 6
gelfiltration column. The column separates the 18 subunit Pol II/Mediator middle mod-
ule complex from excess Rbp4/Rbp7 and Mediator proteins (Figure 18A). The peak
fractions which contain the 18-subunit Pol II/Mediator middle module complex, have
a retention volume between the standard proteins thyroglobulin (669 kDa) and ferritin
(440 kDa) and correspond to 630 kDa apparent molecular weight. Excess Rbp4/Rbp7
does not coelute with excess hexameric middle module. Thus binding of Pol II and
Mediator proteins does not seem to be mediated through direct binding to Rbp4/Rbp7.
Fractions containing the holoenzyme were pooled. When the pooled fractions were
loaded for a second time on the same gelfiltration column the Pol II/Mediator complex
again eluted at the same retention times in stoichiometric amounts, showing that the
complex is biochemically stable (Figure 18B).
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Figure 18: Hexameric middle module binds Pol II: (A) Superose 6 gelfiltration of the
assembled middle module/Pol II holoenzyme. Coomassie stained SDS-PAGE of the
peak fractions are shown next to the corresponding peaks. (B) Second Gelfiltration of
the peak fractions from (A). Silver stained SDS-PAGE shows the contents of the peak.
Elution of the protein is monitored by the absorption at 280 nm.
Several groups have shown that human as well as yeast Mediator binds to the C-
terminal domain (CTD) of the largest subunit of Pol II in vitro (Naar et al., 2002). The
Srb proteins (Srb2, 4, 5, 7, 8, 9, 10, 11 corresponding to MED20, MED17, MED18,
MED12, MED13, CDK8 and cyclinC) were discovered as suppressors of a cold sen-
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sitive phenotype of CTD truncation mutants, pointing to possible Mediator/CTD in-
teractions in vivo (Nonet and Young, 1989; Thompson et al., 1993). I wanted to test
whether the interaction of Pol II and the reconstituted middle module is due to the
CTD of Pol II. I therefore performed Gst pull-down assays using a recombinant Gst-
CTD (Rpb1 residues 1556-1733) and A Gst-linker-CTD (Rpb1 residues 1437-1733)
(Figure 19A). The linker corresponds to a region of the large subunit of Pol II which
connects the structured core to the flexible CTD. No interaction was observed of mid-
dle module and Gst-CTD or Gst-linker-CTD, while the CTD interaction domain of
PCF11 (Meinhart and Cramer, 2004) did interact with both CTD variants, providing
a positive control. (Figure 19). This indicates an interaction of middle module with
the core Pol II rather than with its CTD. Electron microscopy of the holoenzyme also
indicates interactions of Mediator and Pol II in addition to interactions with the CTD
(Asturias et al., 1999; Davis et al., 2002).
Figure 19: CTD interaction: (A) Scheme of the CTD constructs used. (B) Western blot
of the Gst CTD pull down with PCF11 and the hexameric middle module. Detection
was done by anti His antibody.
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2.3 Structural studies of MED25, a target for the acidic activator
VP16
The MED25 subunit of Mediator is unique to higher organisms (Mittler et al., 2003;
Yang et al., 2004). It contains two domains. The von Willebrand domain A (VWA)
binds to human Mediator, and an activator interaction domain (ACID) which binds
the activation domain (AD) of the viral protein VP16. There is only one other protein
known to share the ACID domain. PTOV1 (prostate tumor overexpressed gene) con-
sists of two copies of the ACID. Figure 20 shows the domain organization, sequence
alignment and secondary structure prediction (Rost, 1996) of the ACID. The design of
variants and mutations used for crystallization is based on this alignment.
2.3.1 Purification of ACID
Initial ACID variants comprising the human (hACID, residues 393-548) or the drosophila
(dACID, residues 515-687) domain are massively overexpressed in E. coli and were
purified by a C-terminal His tag. hACID has a pI of 9.8 and copurifies with E. coli
nucleic acids from the expression strain. Purification by Ni NTA and high salt washes
of 1 M NaCl removed bound DNA. Subsequent purification by cation exchange chro-
matography is selective for ACID which is not bound to DNA and resulted in one sin-
gle peak corresponding to the human ACID domain (Figure 21A). Despite the high pI
of 8.9, the drosophila ACID domain did not bind to cation exchange columns. Instead
it was purified by anion exchange chromatography, which removes the contaminants
as well as DNA. In this case the flow-through of the column contained pure dACID.
Gelfiltration of the ACID containing fractions resulted in single peaks, indicating a
single and homogenous species of the ACID domains. SDS-PAGE analysis of the
peak fractions confirmed the purity of the Protein (Figure 21). Pure and homogeneous
material is a prerequisite for crystallization. To ensure complete removal of nucleic
acid contaminations in the protein preparation the absorption at 260 nm was moni-
tored during all purification steps. A characteristic of the ACID domain is the yellow
color of the purified protein solution (Figure 21B). I monitored the yellow color during
the purification by measuring the absorption at 400 nm. The yellow peak coelutes with
the protein (280 nm) during all steps of the purification. This color is not due to bound
contaminants as shown by SDS-PAGE. ICP (Induced coupled plasma) analysis of the
sample did not reveal any metal binding. The pure proteins were subjected to limited
proteolysis and proved to be very stable except for a short C-terminal truncation of
55
2.3 1.3 Structural studies of MED25 2 RESULTS
Figure 20: Primary structure of MED25: (A) Schematic representation of human
MED25 and PTOV1. The Mediator binding von Willebrand domain A (VWA) and
the activator binding domain (ACID) are indicated. PTOV1 consists of two copies of
the ACID domain. (B) Multiple sequence alignment of the ACID of MED25 of differ-
ent species as well as of the two ACIDs of PTOV1 (human and drosophila). Species
are indicated in front of the alignment. Predicted strands and helices are shown below
the alignment as arrows and cylinders, respectively. Residues are highlighted in dark
green, green, light green and yellow according to decreasing degree of conservation.
Dots above the alignment indicate residues chosen for mutation to alanine, arrows
correspond to estimated protease cleavage sites in the dACID.
56
2.3 1.3 Structural studies of MED25 2 RESULTS
dACID (summarized in Figure 20B).
Coexpression of the ACID domain with the complete activation domain (AD) of VP16
(residues 404-490) or VP16H1 (residues 404 to 451) in E. coli leads to an increase of
protein expression, possibly because the unstructured AD binds to ACID and is thus
protected from proteolysis. The proteins could be purified as a stoichiometric complex
by a N-terminal Gst tag on the VP16AD (Figure 21C). A second purification step by
the C-terminal His tag of the ACID domain results in pure, stable and stoichiometric
complexes. Purification by cation exchange or heparin chromatography disrupted the
complex and was therefore omitted.
2.3.2 ACID interacts with DNA
Most Mediator proteins of the head and middle domain have acidic pIs. The very
high pI of ACID was therefore surprising. To test whether the binding to nucleic acids
seen during purification was due to the strong charges of missfolded aggregates of
ACID, we tested the DNA binding ability of the purified protein. Band shift assays
with double stranded DNA of 19, 21, 23 and 25 bp show a shift of the DNA bound to
ACID (Figure 21D). No shift is observed for a shorter double stranded DNA fragment
of 17 bp. However, it is not clear whether DNA binding does point to a special role of
MED25 in the Mediator complex or it is only due to the strong positive charges on the
protein surface.
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Figure 21: ACID purification: (A) SDS-PAGE analysis of the ACID purification by
Ni-NTA (CL: cleared lysate, FT: flow-through, W1, 2: Washing steps, E: elution)
and MonoS (MS) cation exchange chromatography. Sizes of the molecular weight
standards are given next to the gel, as well as the position of ACID. (B) ACID at a
concentration of ~5-10 mg/ml has a light yellow color. (C) SDS-PAGE analysis of
ACID/VP16AD purification by glutathione sepharose. Samples are indicated as in
(A). The molecular weight is indicated on the right. (D) Bandshift assay of purified
ACID with double stranded DNA and increasing amounts of protein (50 pMol, 100
pMol, 200 pMol).
2.3.3 Mapping of a minimal VP16 activation domain
The C-terminal activation domain of VP16 contains two regions, which are responsi-
ble for activation. These have been determined by mutational studies (Walker et al.,
1993). They interact with multiple components of the transcription machinery (Hall
and Struhl, 2002). The activation domain is unfolded in solution (Donaldson and
Capone, 1992) and becomes structured upon interaction with the target proteins (Ue-
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sugi et al., 1997; Shen et al., 1996; Jonker et al., 2005). For crystallization it is therfore
important to determine the exact region of the AD, that interacts with ACID.
The complex of ACID/VP16AD was subjected to partial proteolysis to probe for un-
structured regions. Treatment with proteinase K lead to two defined fragments within
the activation domain as determined by SDS-PAGE (Figure 22). The N-termini of the
two fragments were sequenced by Edman degradation. This revealed a N-terminal
fragment of the AD as well as a fragment starting at amino acid 438. The faster mi-
gration of the fragments compared to the full activation domain indicates a C-terminal
truncation. Because VP16AD consists of two parts with the potential to activate tran-
scription and the end of the first part is after amino acid 451 of the AD, this C-terminal
truncation site was estimated to be at position 451. A variant consisting only of the
N-terminal H1 region of the activation domain still interacted with the ACID domain,
confirming the estimated end of the interaction site. The resulting minimal peptide cor-
responds to amino acids 438 to 451 of the VP16 AD (Figure 22). This is in agreement
with the minimal region for activation as it was determined by (Seipel et al., 1994).
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Figure 22: Proteolysis of ACID/VP16AD complex: (A) SDS-PAGE of a proteinase
K protease digest of a copurified complex of ACID/VP16AD. The names of the pro-
teins as well as the sizes of the Molecular weight standards are indicated. Sequences
determined by Edman sequencing are indicated by arrows next to the corresponding
bands. (B) Schematic representation of the sequence of the VP16 AD. Proteolytic sites
are indicated by arrows above the sequence. Red bars below the sequence show the
fragments corresponding to the identified fragments.
2.3.4 C-terminal truncation of D. melanogaster ACID prevents interaction with
the VP16 AD
During the attempt on structure determination, crystallization setups of the ACID do-
main of two different species have been made. The C-terminus of the ACID domain
of D. melanogaster was sensitive to treatment with the proteases chymotrypsin and
trypsin. Based on these proteolysis experiments, C-terminal truncations (535-698,
535-681, 535-687, 535-711) of this domain were cloned and tested for their ability to
interact with the VP16 AD. All variants except the shortest (535-698) retained their
ability to bind VP16H1 but not a mutant thereof (F442P) (Figure 23).
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Figure 23: Interaction of dACID with Gst-VP16AD: (A) Schematic overview of the
dACID deletion constructs. (B) Schematic overview of the VP16 constructs used the
F442P mutant is indicated by P. (C) Coprecipitation of truncated dACID domains with
Gst-VP16H1 and with the VP16H1 mutant (F442P). Overexpressed ACID (load, the
corresponding bands are marked with *) was precipitated with Gst-VP16H1 and the
mutant. Bound proteins were analyzed by SDS-PAGE and Coomassie staining.
2.3.5 Crystallization trials
Several variants of the ACID domain of two different species have been overexpressed
in E. coli and purified. First, crystallization trials of ACID using 96 well sitting drop
plates were set up with the use of a crystallization robot (4.4.6). Since the ACID do-
main alone did not crystallize, cocrystallization of hACID was tried with a synthetic
peptide of the VP16 AD (residues 438 to 451) and with coexpressed VP16H1. How-
ever, no crystals were obtained. To ensure folding of the protein, one-dimensional 1H
and two-dimensional 1H-1H and NOESY NMR spectra of the shortest variant of
dACID were recorded (Michael Sattler, EMBL Heidelberg). The spectra show that
the protein is folded but seems to have also large regions without secondary structure.
The reason that the ACID domain and its VP16 complexes resist crystallization even
though it is very well overexpressed, pure and homogenous might lie in the strong
positive charges the protein carries. Replacement of putative surface residues hav-
ing long, flexible and charged side chains by alanine might help the protein to crys-
tallize. The idea is to locally reduce conformational entropy and generate contact
forming conformationally homogeneous surfaces. This strategy has been applied by
other groups before (Derewenda, 2004). Four variants of the domain were generated
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Figure 24: NMR spectra of dACID3 (535-681). (A) One dimensional 1H NMR-
spectra. (B) two dimensional 1H-1H and NOESY NMR spectra. (spectra were
recorded by M. Sattler, EMBL Heidelberg).62
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in which charged residues where replaced by alanines (ACID-K413A/K415A/D420A,
ACID-E439A/K442A/E444A, ACID-K480A, ACID-K519/520/521A). All of the mu-
tated residues lie in regions without predicted secondary structure (Figure 20), which
are likely to locate on the surface of the ACID domain. All variants were screened for
crystallization, unfortunately without success.
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3 Discussion
3.1 An E. coli coexpression system to analyze pair-wise interac-
tions within the Mediator middle module and to obtain crystal-
lization-grade Mediator subcomplexes
A significant impediment to high-resolution structure determination of yeast Mediator
stems from its low abundance within yeast cells and the difficulty to obtain the com-
plex in pure form, free from other components of the transcriptional machinery (Myers
et al., 1998; Takagi et al., 2005). Heterologous gene expression of most single Medi-
ator subunits in E. coli leads to insoluble or not properly folded proteins, because the
correct binding partner is absent. During this study I established a recombinant expres-
sion system in E. coli which allowed to study protein-protein interactions within the
middle module of Mediator. Coexpression of subunits often leads to solubly expressed
heterodimeric complexes of interacting subunits.
Using the coexpression approach, I obtained a detailed interaction map between the six
well conserved of the seven proteins in the yeast Mediator middle module (Figure 25).
This map shows the following interactions: MED4-MED7, MED4-MED9, MED4-
MED21, MED7-MED21, MED10-MED21. All of the interacting subunits could be
purified after coexpression in a stoichiometric manner over several chromatographic
steps, showing the stable nature of the interactions. In addition I showed that MED31
contacts several subunits of the middle module, but needs more than one partner for
the formation of a stable complex. It is interesting to note that at least MED7/MED21
can only be obtained in a stoichiometric manner if the proteins are coexpressed. Indi-
vidual expression and subsequent assembly of the two proteins does not lead to a stable
complex. All of these findings are consistent with published data on yeast Mediator
subunit interactions, which stem from coexpression of subunits in insect cells (Kang
et al., 2001; Koh et al., 1998), coimmunoprecipitation (Lee and Kim, 1998), the split
ubiquitin assay (Gromoller and Lehming, 2000a), and from yeast two-hybrid analysis
(Uetz et al., 2000; Guglielmi et al., 2004; Ito et al., 2001). These studies additionally
showed that the remaining subunit of the middle module, MED1, binds to the MED7
N-terminal region. The Med7 N-terminal region also binds MED9 (Guglielmi et al.,
2004; Kang et al., 2001).
MED31 is a highly conserved protein that copurifies with metazoan Mediators. In
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yeast, MED31 was genetically associated with transcription for a long time but only
recent reports confirmed copurification with S. cerevisiae as well as S. pombe Mediator
complex (Guglielmi et al., 2004; Linder and Gustafsson, 2004; Takagi et al., 2005).
Using the coexpression strategy I found interactions of MED31 with MED4, MED7,
MED10 and MED21. Therefore MED31 is an integral part of the Mediator middle
module. The interactions to MED10 and MED21 were also observed by Guglielmi et
al. in yeast two hybrid screens. The interactions to MED4 and MED7 are in keeping
with data from a large-scale yeast two hybrid screen (Ito et al., 2001). One possible
reason why MED31 was not identified earlier as a Mediator subunit is its size. MED31
may have escaped earlier detection by SDS-PAGE due to its small size of 14.7 kDa.
Furthermore small subunits are stained less than their bigger interaction partners and
might be missed by visual inspection of the SDS-PAGE.
MED1 is the only protein of the middle module which could not be obtained using
the coexpression-copurification method. MED1 is a 64 kDa protein which is only
weakly conserved from yeast to human. In yeast multiple interaction partners have
been identified by two hybrid analysis (Uetz et al., 2000; Guglielmi et al., 2004; Ito
et al., 2001). Beside the binding to MED4, MED9 and MED7 in the middle module,
MED1 seems to form a bridge to the tail module: it binds to MED14, as well as MED5
(Guglielmi et al., 2004). Folding of MED1 can be dependent on these proteins or on
the cellular environment of eukaryotic cells which is not provided by E. coli. Except
for MED1, expression of two interacting subunits in one cell could promote folding of
the subunits and allowed for their recombinant expression. Subsequent copurification
gave an indication about the stability of these interactions. Amounts and quality of the
copurified heterodimers were sufficient for structural studies.
3.2 The MED7/MED21 structure
Limited proteolysis identified the non-structured regions within the MED7/MED21
heterodimer and subcloning of the stable part allowed to obtain a crystallizable sub-
complex. Initial crystals diffracted to a maximum of 3.3 Å resolution and were very
radiation sensitive. MAD data of selenomethionine crystals was obtained to only
3.8 Å and did not allow structure determination. Removal of the protease sensitive
C-terminus of MED21 and introduction of additional methionines improved the crys-
tals and enhanced the anomalous signal in selenomethionine derivatives. MAD data
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Figure 25: Mediator architecture: (A) Outline of Mediator bound to Pol II accord-
ing to electron microscopy (Davis et al., 2002). The suggested head, middle and tail
modules are indicated. (B) Mediator subunit architecture. All depicted subunits are
at least partially conserved throughout eukaryotes except MED2 and MED3. The per-
centage of sequence homology between yeast and human subunits is indicated for the
better conserved subunits. The four-subunit CDK8/CyclinC module and the putative
Mediator subunit MED5 have been omitted. For size comparison, the structure of the
MED7/MED21 complex and the Pol II-Mediator complex are drawn to scale. Black
rectangles indicate direct protein-protein interactions detected in this study.
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to 3.5 Å allowed structure solution. The subcomplex contains the conserved parts of
MED7 and MED21. The MED7/MED21 heterodimer binds MED6 in the head mod-
ule and the most conserved subunits (MED4, MED9, MED10, MED31) of the middle
module. The interaction mapping established the MED7/MED21 complex together
with MED31 as the conserved assembly scaffold of the middle module. The struc-
ture of MED7/MED21 shows a very elongated protein complex. Even more elongated
structures can be expected for the complexes containing MED7/MED21 and MED4
or MED4/MED9 in addition. Analysis of the recombinant complexes by gelfiltration
showed very short retention times. Sequence-based predictions of secondary struc-
ture (Rost, 1996) and coiled-coils (Lupas et al., 1991) strongly suggest that subunits
MED9, MED10 and MED4 are largely helical and form coiled-coils that may medi-
ate the strong subunit interactions observed here, and may span large distances on the
Pol II surface.
3.2.1 Conserved Mediator core architecture
My data show that the MED7/MED21 heterodimer tightly binds to other highly con-
served Mediator subunits via its evolutionarily conserved regions and thus plays a
central architectural role within Mediator. Analysis of the molecular surface of the
MED7/MED21 heterodimer reveals that the majority of the surface is hydrophobic,
consistent with the observed extended interactions with other subunits. Four con-
served surface patches (Figure 26A) may serve as protein interaction sites and befit
the architectural role of the MED7/MED21 heterodimer. Patch 1 and 2 are near the
hinge region. Patch 2 includes the highly conserved N-terminal helix α1 of MED21
(residues R4, Q7, L8), and a part of MED21 helix α2 (residues L76, S79, L80, Figure
26A). Since the highly conserved seven N-terminal MED21 residues are required for
MED6 binding (Gromoller and Lehming, 2000a), I propose that patch 2 constitutes the
MED6 binding site. Patches 1, 3 and 4 may bind to subunits of the middle module, but
may also be involved in interactions with Pol II. Patches 3 and 4 are involved in crystal
contacts. Patch 3 corresponds to the open end of the coiled-coil that stacks against a
neighboring coiled-coil in the crystals (Figure 9B), and patch 4 mediates dimerization
of bundle domains of neighboring MED7/MED21 heterodimers in the crystals (Fig-
ure 9C). The resulting two types of tetramers in the crystal do not show additional
conserved surface patches (Figure 26B, C). Taken together, the high conservation of
the MED7/MED21 heterodimer, its many interactions with conserved subunits, and its
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Figure 26: Conserved surfaces of MED7/MED21 (A) Conserved surface patches on
the MED7/MED21 complex. The views are as in Figure 9A. Conserved residues are
colored according to Figure 9. Four conserved surface patches are indicated. (B)
Surface representation of the tail to tail heterotetramer observed in the crystal packing.
The view is as in Figure 9B. Conserved residues are colored according to Figure 9
(C). Surface representation of the head to head heterotetramer observed in the crystal
packing. The view is as in Figure 9C. Residues are colored in dark green, light green
and yellow according to decreasing degree of conservation.
extended conserved hydrophobic surface patches all indicate that the structural archi-
tecture of the central region of the core Mediator is the same in all species.
3.2.2 Conserved hinges and Mediator function
Electron microscopy of free yeast Mediator and Mediator bound to Pol II revealed
a dramatic structural rearrangement (Davis et al., 2002). Whereas free Mediator is
relatively compact, it becomes extended upon Pol II binding, and is wrapped around
the polymerase surface in the Pol II-Mediator complex (Figure 25A). This transition
apparently involves a large change in the relative position of the Mediator middle and
head modules (Davis et al., 2002). Our data suggest that the MED6 subunit plays
a central role in this process, because it bridges between two modules of the core
Mediator. Secondary structure prediction for MED6 reveals extended loop regions
and helices with low probability (Rost, 1996), indicating a strong intrinsic flexibility
for MED6. MED6 may form a conserved flexible connection between the head and
middle modules. The bridging role of MED6 is relevant for Mediator function in vivo.
In agreement with the essential bridging role a point mutation in MED17 suppresses
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temperature-sensitive mutations in the N-terminal region of MED6 that weaken the
interaction with MED17 (Lee and Kim, 1998). The interaction of MED21 with MED6
is apparently essential in vivo, as a deletion mutant of yeast lacking the 15 N-terminal
residues of MED21, which does not bind MED6 in vitro, is not viable (Gromoller and
Lehming, 2000b).
Strong structural changes have also been observed in the mammalian Mediator coacti-
vators CRSP and ARC upon binding of activator proteins (Taatjes et al., 2002, 2004b).
In addition to the MED6 hinge, the intrinsic flexibility of the MED7/MED21 hetero-
dimer may account for these conformational changes. The hinge region between the
two domains of the heterodimer may allow flexibility within the middle module, be-
cause the relative locations of subunits bound to surface patch 3 on the coiled-coil
and patches 1, 2, and 4 on the bundle domain can change. Binding of MED6 to the
hinge region of the MED7/MED21 heterodimer may restrict or coordinate hinge mo-
tions. The repositioning of different parts of the core Mediator, enabled by conserved
hinges as suggested here, and triggered by the interaction with various partners, may
be crucial for Mediator function.
3.3 Larger complexes
I used the crystallized MED7/MED21 subcomplex as a scaffold for the cocrystalliza-
tion with additional subunits. Despite the very stable nature of MED4/MED7/MED21
and MED10/MED7/MED21 complexes during purification, MED4 and MED10 were
not visible in the electron densities. There are, however, two findings indicating the
presence of the two additional proteins in the crystals. First, both complexes crystal-
lized easier and also in different conditions than the original MED7/MED21 hetero-
dimer. Second, analysis of the crystal contents by mass spectrometry and SDS-PAGE
revealed the presence of MED10 and MED4 in their respective crystals. In addition,
MED4 is a 36 kDa protein, bigger than the crystallized MED7/MED21 heterodimer.
Therefore more than 50 % of the protein content in the crystallization drop consisted
of MED4. Such a high percentage of MED4 in the drop would be likely to inhibit
crystal growth of the MED7/MED21 complex.
The invisibility of MED4 and MED10 in the electron densities might be due to high
mobility of the proteins within the crystals. Such high mobility could arise if the
proteins bind to mobile regions with high B-factors, like the loop between helix α1
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and helix α2, or the C-terminus of MED21. Binding of MED10 to the loop region of
MED21 is supported also by limited proteolysis experiments where MED10 stabilizes
the MED7/MED21 complex, possibly protecting its largest loop region. An answer to
this problem might lie in the additional proteins of the middle module. These proteins
could stabilize MED4 and MED10 by binding the two proteins and at the same time
bind to the surface patches (Figure 26) in the MED7/MED21 heterodimer. Thereby
the flexible loops of the MED7/MED21 heterodimer as well as the additional proteins
would become stable. A first step in this direction is the reconstitution of the four- and
six-subunit middle modules.
3.3.1 A reconstituted Mediator middle module
Structural analysis of the entire Mediator complex has so far been limited to low reso-
lution EM images due to non-homogeneous samples of purified endogenous Media-
tor/Pol II holoenzyme. These reports were very informative, showing the conforma-
tional changes as well as the overall structural conservation of Mediator complexes
from yeast to human. However, to understand the mechanism of Mediator as a coac-
tivator, detailed structural information is needed. Such detailed structural analysis
requires well defined and homogeneous samples. Because of its modular organization,
its low abundance and the many interactions to activators and the transcription machin-
ery, it is difficult to purify endogenous Mediator as a homogeneous complex. There-
fore we reconstituted Mediator subcomplexes from recombinant proteins expressed
in E. coli. Coexpression of single subunits allowed their recombinant expression in
soluble form. Assembly of two subcomplexes of two and four proteins lead to the
six-subunit middle module. This middle module contains all the highly conserved Me-
diator core proteins except for MED1 (Figure 27). It is a well defined, homogeneous
and stoichiometric complex of known composition and therefore suited for high res-
olution structural analysis by cryo EM or crystallography. A first quality control by
negative stain EM shows single particles of the expected size.
With this complex in hand, a Pol II/Mediator middle module complex could be re-
constituted. To my knowledge the reconstituted six-subunit middle module is the first
recombinant Mediator subcomplex shown to bind purified Pol II. We now have a tool
to answer questions of how Mediator integrates the signals from transcription factors
to the polymerase. For instance, it is still unclear which subunits of Mediator contact
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the polymerase. Approaches using yeast two hybrid screens did reveal intersubunit
interactions of Mediator but none to the polymerase (Guglielmi et al., 2004, personal
communication M. Werner). Initial binding studies done with the purified recombinant
dimeric and trimeric Mediator subcomplexes (this study) did not bind to endogenously
purified Pol II. It is possible that there are no strong contacts between single subunits
of the two complexes but each interaction surface is made up of more than one protein,
explaining why Mediator-Pol II interactions are not detectable in yeast two hybrid
screens. Published EM data show multiple interaction sites between Mediator and
Pol II (Asturias et al., 1999). It is likely that there are multiple weak cooperative con-
tacts adding up to the interaction. The interaction of Pol II and Mediator has to be
reversible when the Pol II starts transcription and Mediator remains at the promoter.
Multiple weak contacts are possible to break by conformational changes, while this is
unlikely for a single strong interaction site.
The binding of the middle module to the polymerase and its stable association also dur-
ing repeated gelfiltration chromatography indicates that the in vitro-assembled com-
plex is properly folded and reconstituted. No binding of the reconstituted middle mod-
ule to the CTD was observed. The reconstituted middle module associates with Pol II.
Therfore the CTD alone is not sufficient for middle module binding but the core of Pol
II is needed for the interaction. However, Kang et al. coexpressed a six subunit Medi-
ator middle module (consisting of MED1/MED4/MED7/MED9/MED10/MED21) in
insect cells which could coprecipitate Gst-CTD. Their complex contained additionally
MED1 but not MED31. The difference seen in CTD binding might lie in the different
subunit composition or post-translational modification of the complexes. E. coli does
not allow for phosphorylation of the subunits while this is possible in insect cells. It
was reported that MED4 is phosphorylated in holoenzyme complexes (Guidi et al.,
2004). Different subunit composition or phosphorylation could also induce a different
conformation of the module. It was shown by EM that the open (polymerase bound)
conformation of Mediator also occurs at high pH or, partially, in the presence of the
CTD (Asturias et al., 1999).
3.4 Conservation within Mediator subunits
Mediator has been conserved during evolution. EM studies revealed similarities in the
overall structures of yeast and mammalian Mediator complex (Asturias et al., 1999;
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Dotson et al., 2000). Identification of orthologoues of 22 of the 25 S. cerevisiae sub-
units (all subunits of S.cerevisiae except MED2, MED3 and MED5) provide a rational
for the overall structural similarities observed. The limited overall sequence conser-
vation from yeast to human is possibly sufficient for conservation of the folds of the
single subunits and their intersubunit contacts.
Most of the Mediator subunits are only weakly conserved from yeast to human. Espe-
cially in the tail module only single domains, if at all, have orthologoues in yeast and
human. Therefore large parts of the surface of the Mediator complex cannot be con-
served. This could allow the Mediator to accommodate the huge increase in regulatory
inputs during evolution, emerging from novel gene specific transcription factors.
Some subunits however, are stronger conserved than needed for preservation of the
overall fold. Moreover, the degree of conservation is not linked to whether these pro-
teins are essential in yeast or not. Together with CDK8/CyclinC, MED31 is the highest
conserved Mediator subunit (50 % homology) (Linder and Gustafsson, 2004). None
of these proteins are essential for yeast viability (Giaever et al., 2002; Fan and Klein,
1994). A reason for the higher conservation is preservation of enzymatic activity as
it is observed for the CDK8/CyclinC module. MED31 together with MED7, MED10
and MED21 are the highest conserved subunits of the core Mediator (Figure 27). This
might be because the middle module is the part of Mediator which interacts with the
(highly conserved) Pol II as determined in this study. The flexibility observed for the
MED7/MED21 complex and predicted for MED6 might require such a high conser-
vation. Indeed, conserved residues of MED7 and MED21 map to the hinge region
(Figure 9).
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Figure 27: Mediator conservation: the Mediator subunit architecture is shown as in
figure 25B. Head middle and tail modules are indicated. All depicted subunits are
at least partially conserved throughout eukaryotes, except MED2 and MED3. The
percentage of sequence homology between yeast and human subunits is indicated for
the better conserved subunits. The color code is given on the left. S. cerevisiae has
long insertions in the subunits MED6 and MED18, the conservations given are for the
whole proteins.
3.5 Towards the structure of an activator interaction domain
The activator interaction domain (ACID) of MED25 is a small 20 kDa protein domain.
During this study I established purification protocols for human and drosophila ACID.
Analysis by proteolytic digests revealed the stable nature of the domain. Except for the
C-terminus of the drosophila protein no degradation was observed, indicating folding
of the domain. Recombinant ACID retains its ability to bind to VP16, again pointing
to a folded domain. Nevertheless no crystals could be obtained. Therefore I did differ-
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ent ACID truncations and mutations. A C-terminally truncated version consisting of
dACID amino acid residues 535-681 lost the VP16-binding ability. N-terminal trun-
cation of hACID and recombinant expression did not lead to soluble protein, possibly
because the deleted N-terminus is needed for folding. Outgoing from these results I
generated the minimal hACID and introduced mutants to remove patches of strongly
charged and flexible amino acids in regions without any predicted secondary structure.
The mutations to alanine might generate surfaces which potentially could be involved
in crystal contacts (Derewenda, 2004).
Purified concentrated ACID has a yellow color. This is not due to metal binding of
the protein as shown by ICP analysis. There might be a cofactor, which has a yellow
color such as NADH and binds to the protein such that it can not easily be removed
by conventional chromatography methods. However, there is no enzymatic activity
known, that could explain the presence of such a cofactor.
I found that ACID copurifies with nucleic acids. Electrophoretic mobility shift assays
of purified recombinant protein show DNA binding in vitro. ACID has a strikingly
high pI of 9.7, which differs from most other Mediator subunits. The DNA binding is
not only due to the high charges of nucleic acids, since it is also dependent on the length
of the DNA used. Together with the notion that MED25 is associated in part with the
chromatin fraction of human cells (Blazek, 2005) it might be that the DNA binding
observed is not just an artefact which stems from the highly charged domain, but it
can indeed associate with nucleic acids. ACID interacts with the activation domain of
VP16 (Mittler et al., 2003; Yang et al., 2004). The core of VP16 binds to the DNA and
and cellular DNA binding factors, like OCT1 and HSF1 (Liu et al., 1999) it is possible
that ACID contributes to this interaction.
The protein domain is small, highly soluble and stable and should therefore be an ideal
target for crystallization. Despite many efforts to crystallize ACID, I could not obtain
protein crystals. Additional stabilization of the domain by the addition of VP16H1 or
the mapped VP16 interaction peptide did only lead to two dimensional protein crystals
which do not allow for structure determination. Nevertheless NMR tests of the protein
solution showed that the protein is folded. Given the small size of less than 20 kDa,
and the high solubility it is an ideal target for structure determination by NMR.
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3.6 Conclusion and Outlook
During this thesis a recombinant coexpression system in E. coli was established, which
allowed analysis of the pairwise interactions within the Mediator middle module as
well as the generation of crystallization grade subcomplexes. Solution of the structure
of the MED7/MED21 heterodimer in two different crystal forms revealed a flexible
hinge, which could be responsible for the large conformational changes Mediator un-
dergoes upon polymerase binding. Further, a protocol for the reconstitution of a re-
combinant middle module has been established. Amounts and quality of the middle
module complex are sufficient for structural studies. This recombinant middle module
is a minimal Mediator module required for polymerase binding.
Structural analysis of the Mediator middle module will clarify the role of the pro-
posed conformational changes seen in the MED7/MED21 structures. Further research
will have to focus on complexes of the Mediator middle module together with the
polymerase. Medium resolution EM or crystal structures of the Pol II/middle module
complex and subsequent docking of high resolution substructures are necessary to elu-
cidate how Mediator binds and regulates the polymerase. Activators like VP16 bound
to single domains of the Mediator will further enlarge our knowledge of the signal
transmission from activators to Mediator. A long term goal of the study started here
is the in vitro reconstitution of a functional core Mediator and its structural analysis
alone as well as in complex with Pol II and the general transcription factors.
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4 Experimental procedures
4.1 General Methods
4.1.1 Bacterial strains
strain description source
DH5α F’ ∆80dlacZ∆M15 ∆(lacZYA-argF)U169 deoR
recA1 endA1 hsdR17(rK
- mK
+) phoA supE44 λ- thi-
1 gyrA96 relA1
Woodcock
et al., 1989
XL-1 blue
strain
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1
lac[F’ proAB laclqZ∆M15Tn10(Tetr)]
constitutive promoter
Stratagene
BL21-
Codon Plus
(DE3)-RIL
B F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ(DE3)
endA Hte [argU ileY leuW Camr], extra copies
of argU, ileY and leuW tRNA genes on a ColE1-
compatible plasmid with chloramphenicol resis-
tance marker, protease deficiency, chromosomal T7-
polymerase gen
Stratagene
BL21-
(DE3)
B F- ompT hsdS(rB- mB-) dcm+ Tetr gal λ (DE3)
endA Hte, protease deficiency, chromosomal T7-
polymerase gen
Stratagene
B834 E. coli (DE3) (hsd metB) Budisa
et al., 1995
Table 6: Bacterial strains
4.1.2 Plasmids
# Insert Vector Restriction
sites
Tags Remarks Expression
level
1 MED10 pET21b Nde I, Not I His OK
2 MED4 pET21b Nde I, Not I His OK
3 MED21 pET24d
GstTEV
Sal I, Not I His bicistron I 2nd RBS in
ORF
4 MED21 pET24d
GstTEV
Sal I, Not I His bicistron I 2nd RBS mu-
tated
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5 MED4
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I 2nd RBS in
ORF
6 MED10
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I 2nd RBS in
ORF
7 MED7
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I 2nd RBS in
ORF
8 MED6
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I
not sequenced
2nd RBS in
ORF
9 MED10
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I none
10 MED4
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I none
11 MED7
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I none
12 MED6
MED21
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I
not sequenced
none
13 MED10
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II good
14 MED4
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II good
15 MED7
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II good
16 MED6
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II good
17 MED7
MED4
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II good
18 MED7
MED4
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I expressed
19 spMED7 pET15b Nde I, BamH I His Clas
Gustaffson
Thrombinsite
good
20 spMED10 pET15b Nde I, BamH I His Clas
Gustaffson
Thrombinsite
good
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21 spMED4 pET15b NdeI, BamH I His Clas
Gustaffson
Thrombinsite
22 spCDK8 pET15b NdeI, BamH I His Clas
Gustaffson
Thrombinsite
23 spMED10
scMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
chimera
bicistron II
none
26 spMED4
scMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
chimera
bicistron II
none
28 spMED7
scMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
chimera
bicistron II
good
30 MED4∆C731 pET21b Nde I, Not I His mutation unstable
32 MED4∆C625 pET21b Nde I, Not I His mutation expressed
33 MED4∆C625
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II unstable com-
plex
34 MED4∆C731
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II unstable com-
plex
35 spMED21 pET24d
GstTEV
Nde I, Not I His bicistron I
36 MED21∆C37 pET24d
GstTEV
Nde I, Not I His bicistron I none
37 MED10
MED21∆C37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II none
38 MED4∆C625
MED21∆C37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II none
39 MED6
MED21∆C37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II none
40 MED7
MED21∆C37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II none
41 spMED10
spMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
bicistron II none
42 spMED4
spMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
bicistron II none
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43 spMED7
spMED21
pET21b Nde I, BamH I
Sal I, Not I
none
His
bicistron II good
44 MED4
MED21∆C37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II none
45 MED7∆N102
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II very good
46 MED10
MED7
MED21
pET21b Nhe I, EcoR I
EcoR I, Sal I
Sal I, Not I
none
none
His
tricistron I expressed
47 MED7 pET21b Nde I, Not I His Claudia
Buchen
expressed
48 MED7∆N102
MED21
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II very good
49 MED6
MED21
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
50 MED7
MED21∆C104
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I n.a.
51 MED7
MED21∆N37
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I n.a.
52 MED7
MED21∆N37∆C104
pET24d
GstTEV
Nhe I, EcoR I
Sal I, Not I
Gst
His
bicistron I n.a.
53 MED7
MED21∆C104
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
54 MED7
MED21∆N37
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
55 MED7
MED21∆N37∆C104
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
56 MED7∆N121∆C205
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
57 MED7∆N102∆C207
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
58 MED7∆N102,
MED21
pET24b Nhe I, EcoR I
Sal I, Xho I
none
none
bicistron II very good
79
4.1 General Methods 4 EXPERIMENTAL PROCEDURES
59 MED10∆N9 pET21b Nde I, EcoR I none weak
60 MED10 pET21b Nde I, EcoR I none expressed
61 MED7∆N121
MED21
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
62 MED7∆N102
MED21∆C104
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
63 MED7∆N102
MED21∆N37∆C103
pET21b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
64 MED7∆N102∆C207
MED21
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II expressed
65 hACID1 393-548 pET21b Nde I, Xho I His Thomas
Uhlmann
very good
66 MED7∆N102∆C207
MED21
pET24b Nhe I, EcoR I
Sal I, Xho I
none
none
bicistron II very good
67 MED7∆N102∆C205
MED21∆N37
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II very good
68 MED7∆N102∆C205
MED21∆N37∆C103
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II very good
69 MED7∆N102∆C205
MED21∆C103
pET24b Nhe I, EcoR I
Sal I, Not I
none
His
bicistron II very good
70 MED7∆N102∆C205
MED21∆C132
pET21b Nhe I, EcoR I
Sal I, Not I
none
none
MED21
mutation:
L5M/L119M/
L125M
bicistron II
very good
71 hACID1393-548 pET24b Nde I, Not I none very good
72 MED7∆N102∆C205
MED21∆C132
pET21b Nhe I, EcoR I
Sal I, Not I
none
none
MED21
mutant:
L5M/L119M/
L125M
bicistron II
very strong
73 MED9 pET21b Nde I, BamH I none BamH I
in coding
sequence
n.a.
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74 VP16 pGFxcT01 Gst Michael
Meisterernst
weak
75 MED9
MED4
pET21b Nde I, BamH I
Sal I, Not I
none
His
bicistron II very strong
76 MED1 pET24d Nco I, Not I His not detectable
77 MED10 pET24b Nde I, Not1 His OK
78 hACID1 393-548 pET24b Nde I, Xho I His Thomas
Uhlmann
good
79 VP61H1 pGFxcT01 BamH I, EcoR
I
Gst expressed
80 MED6∆C1-214 pET11a His Claudia
Buchen
weak
81 VP61H1Mut pGFxcT01 BamH I, EcoR
I
Gst Michael
Meisterernst
expressed
82 MED7∆N102∆C205
MED21
pET24b Nhe I, EcoR I
Sal I, Not I
none
none
MED7
mutant:
L34M/L40M/
bicistron II
n.a.
83 MED6 pET11a His-
Flag
Claudia
Buchen
weak
84 MED21 pET24b Nde I, Not none expressed
85 MED9∆C134
MED4
pET21b Nde I, BamH I
Nde I, Not I
none
His
not stoichio-
metric
86 MED7∆N102∆C205
MED21∆C132
pET24b Nhe I, EcoR I
Sal I, Not I
none
none
MED21
mutant:
L5M/L119M/
L125M
bicistron II
very strong
87 MED6 pGEX3X His 88 without
MED17
weak
88 MED17∆N241-688
MED6
pGEX3X Gst
His
Sabine
Hoeppner
Xa site
weak
89 dACID1 514-687 pET24b Nde I, Xho I His very strong
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90 dACID2 514-674 pET24b Nde I, Xho I His very strong
91 MED4 pET21b Nde I, Xho I none very strong
93 dACID3 514-656 pET24b Nde I, Xho I His good
94 dACID4 514-663 pET24b Nde I, Xho I His very strong
95 MED31 pET24d Nco I, Not I none weak
96 MED31
MED10
pET24d Nco I, EcoR I
Sal I, Not I
none
His
bicistron III good
97 CTD linker
(1437-1773)
pET24d
GstTEV
Nhe I, BamH I Gst TEV site weak
98 CTD
(1556-1773)
pET24d
GstTEV
Nhe I, BamH I Gst TEV site weak
99 MED9
MED4
pET21b Nde I, BamH I
Sal I, Xho I
none
none
bicistron II very strong
100 MED31
MED9
MED4
pET24d Nco I, EcoR I
EcoR I, Sal I
Sal I, Xho I
His
none
none
tricistron II n.a.
101 MED31
MED9
pET24d Nco I, EcoR I
EcoR I, Sal I
His
none
bicistron III n.a.
102 MED31 pET24d Nco I, EcoR I His expressed
103 MED31∆N pET24d Nco I, EcoR I His weak
104 MED10
MED7
MED21
pET21b Nhe I, EcoR I
Nco I, Sal I
Sal I, Xho I
none
none
none
tricistron I good
105 hACID2 394-543 pET21b Nde I, Not I His good
106 hACID2 394-543 pET21b Nde I, Not I none n.a.
107 hACID2 394-543 pET21b Nde I, Not I His K411/413A
D418A
good
108 hACID2 394-543 pET21b Nde I, Not I none K411/413A n.a.
109 hACID2 394-543 pET21b Nde I, Not I His E437/442A
K440A
good
110 hACID2 394-543 pET21b Nde I, Not I none E437/442A
K440A
n.a.
111 hACID2 394-543 pET21b Nde I, Not I His K478A good
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112 hACID2 394-543 pET21b Nde I, Not I none K478A n.a.
113 hACID2 394-543 pET21b Nde I, Not I His K518/519/
520A
good
114 hACID2 394-543 pET21b Nde I, Not I none K518/519/
520A
n.a.
Table 8: Plasmids
4.1.3 Growth media
Media Reference composition
LB (Miller,
1972)
1 % tryptone; 0.5% yeast extract; 0.5% NaCl
Minimal
Media
Budisa
et al., 1995;
Meinhart
et al.,
2003a
7.5 mM ammonium sulfate, 8.5 mM NaCl, 55 mM
KH2PO4, 100 mM K2HPO4, 1mM MgSO4, 20mM
glucose, 1 µg/l Trace elements (Cu2+, Mn2+, Zn2+,
Mo4
2-), 10 mg/l Thiamine, 10 mg/l Biotine, 1 mg/l
Ca2+, 1 mg/l Fe2+, 100 mg/l amino acids (A, C, D,
E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, Y) , 100
mg/l selenomethionine.
Table 9: Growth media
supplements stock solution in Media
ampicilin 100 mg/ml in H2O 100 mg/l
kanamycin 50 mg/ml in H2O 50 mg/l
chloramphenicol 50 mg/ml in ethanol 50 mg/l
IPTG 1 M in H2O 0.5 mM
Table 10: Supplements
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4.1.4 Bioinformatic tools
Homology searches and alignments Homologoues sequences were found using the
NCBI BLAST and PSI BLAST-Server: http://www.ncbi.nlm.nih.gov/BLAST/ or from
the publication of Boube et al. (Boube et al., 2002). Multiple sequence alignments
were done with ClustalW of the program MaC Vector (accelrys) using default settings
and displayed by the programs Amas and Alscript (Barton, 1993).
Secondary structure prediction Secondary structure prediction was done using the
PredictProtein (http://cubic/bioc/columbia/edu/predictprotein.html) secondary structure
prediction surfer. Generally a multiple sequence alignment was sent, since the accu-
racy of secondary structure prediction depends on the quality of the alignment. For pre-
diction of coiled-coil regions in the proteins the program coils (www.ch.embnet.org/
software/COILS_form.html) was used.
Calculation of molecular weight, absorption coefficient and PI Calculation of
properties of the proteins which are important for the design of the purification strategy
as the PI were determined using ProtParam (www.expasy.org/tools/protparam.html).
The absorption coefficients and molecular weights used for quantitation were obtained
from the same server.
4.1.5 Protein expression and selenomethionine labeling
Proteins were routinely expressed recombinantely in E. coli. Plasmids containing the
desired protein variants were transformed into competent E. coli BL21 DE3 (Strata-
gene). Cells were grown at 37◦ C in LB medium supplemented with the antibiotic
corresponding to the resistance cassette of the plasmid. Once the cells grew to an
OD600 of 0.5 cultures were cooled on ice for 30 min. Protein expression was induced
by addition of 0.5 mM IPTG and cells were grown at 20◦ C over night. Cells were
harvested by centrifugation (5000 rpm, SLS6000 rotor) at 4◦ C, resuspended in lysis
buffer (see corresponding purification) and flash frozen in liquid nitrogen. Cell pellets
were stored at -80◦ C.
For selenomethionine labeling of MED7∆N∆C/MED21, MED7∆N∆C/MED21D∆C,
MED7∆N∆C/MED10His/MED21His and MED4His/MED7∆N∆C/MED21His plas-
84
4.1 General Methods 4 EXPERIMENTAL PROCEDURES
mid DNA containing the corresponding genes were transformed into the methionine
auxotroph E.coli strain B834 (DE3) (Stratagene). Bacteria were grown in LB medium
supplemented with the appropriate antibiotic at 37◦ C to an OD600 of 0.5. Cells were
harvested and resuspended in the same amount of minimal medium (Table 9) supple-
mented with selenomethionine (100 mg/l) and antibiotics. Cells were grown until the
OD600 increased by 0.2 at 37
◦ C to deplete the medium of any residual methionine.
Cultures were cooled on ice for 30 min and protein expression was induced by the
addition of 0.5 mM IPTG. Protein was expressed over night at 18◦ C. Incorporation of
selenomethionine was confirmed by mass spectrometry of the purified proteins.
4.1.6 Limited proteolysis experiments
For chymotrypsin and trypsin treatment 1 µg of the corresponding protease was added
to 20 µg to 50 µg of purified protein. Digests were done in the buffers used for gelfil-
tration and supplemented with CaCl2 to a final concentration of 4 µM. The mixture
was incubated at 37◦ C for 1 min, 3 min, 10 min, 30 min, and 60 min. The reactions
were stopped by the addition of SDS sample buffer and were heated immediately to
95◦ C for 5 min.
For proteinase K treatment 1 µl of dilutions of proteinase K (3 µg/µl, 0.3 µg/µl, 0.03
µg/µl, 0.003 µg/µl) were added to the protein samples. The mixtures were incubated
on ice for 1 h. The reactions were stopped by the addition of sample buffer and boiling
as above. All samples were analyzed by SDS-PAGE. Bands of interest were passively
transfered to PVDF membrane and analyzed by Edman sequencing as described in
4.1.7.
4.1.7 Protein Analysis
Protein separation by SDS-PAGE For separation of protein samples glycine-SDS-
PAGE (10 % - 20 % acrylamide; Laemmli, 1970) was performed. Gels were then
either subjected to protein transfer for Western-blot or directly stained with Coomassie
(SIGMA) solution. Silver staining (Bloom et al., 1987) was performed when very low
amounts of proteins had to be visualized.
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Passive adsorption of electrophoresis samples onto PVDF Membranes and Ed-
man sequencing For N-terminal sequencing proteins were separated on SDS-PAGE
and stained with coomassie. The protein band of interest was excised and dried in a
speed vac. After drying the piece of gel was rehydrated in 20 ml of 200 mM Tris
pH 8.5 (room temperature), 2 % SDS. Then 100 µl of distilled water was added to
set up a concentration gradient together with a small piece of pre wet (ethanol) PVDF
membrane. Once the solution turned blue 10 µl of methanol was added as a catalyst.
After 1 to 2 days the solution became clear and the membrane piece blue, indicating a
complete transfer. The membrane was washed 5 times with 10 % Methanol vortexing
30 sec each time. The Protein was N-terminally sequenced from the dry membrane in
a PROCISE 491 sequencer (Applied Biosystems).
4.1.8 Gelfiltration experiments and calculation of the hydrodynamic radius from
the structure
To estimate the molecular weight of proteins and complexes, analytical gelfiltration
chromatography was performed in the corresponding protein buffers. A Superose-6
HR gelfiltration column (Amersham) was used for these experiments. The column
was calibrated with the standard proteins thyroglobulin (669 kDa), ferritin (440 kDa),
catalase (232 kDa) and aldolase (158 kDa) (Amersham) immediately before the exper-
iment. To obtain an estimate of the stoichiometry of the MED7/MED21 complex the
hydrodynamic radii of monomers and dimers were compared to those of the standards.
The hydrodynamic radii of all proteins were calculated with the program HYDROPRO
(Garcia De La Torre et al., 2000) from the structures of the corresponding proteins.
4.1.9 Static light scattering
Static light scattering measurements were performed with a triple detector TDA (vis-
cotek) connected to a Superose 6 gelfiltration column equilibrated with 150 mM KCl,
10 mM Hepes pH 7.3, 5 mM DTT. 200 µl protein with a concentration of 1.8 mg/ml
was injected onto the column. The concentration/volume was calculated from the
UV absorption and extinction coefficient. With this information the refractive in-
dex/volume was calculated by means of the refractive index detector. Refractive index,
UV and viscosity were followed during the measurement. The hydrodynamic radius
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and the molecular weight were calculated using the static light scattering software from
viscotek with the calculated refractive index.
4.2 The middle module
4.2.1 Strategy for the expression of the middle module proteins
Most of the middle module proteins are only very poorly soluble when expressed
alone. This problem was overcome using multicistronic expression, were two ore more
open reading frames are under the control of one single promoter. During transcription
the open reading frames are transcribed onto one single mRNA and thus translation of
all proteins can occur close in time and space. This allows the nascent polypeptides
to associate with their partners and fold correctly. To coexpress proteins on different
vectors cells were cotransformed with plasmids containing the additional protein and
a different antibiotic resistance cassette .
4.2.2 Cloning
Proteins of the middle module were cloned into pET 21b or pET 24b (Novagen) with
or without C-terminal hexahistidine tag (His) according to table 8. For bicistronic
expression of different middle module proteins together with MED21His the genes
of the corresponding proteins were cloned into the pET21b (Novagen) or pET 24b
(Novagen) vector using the restriction sites Nhe I and EcoR I. Having Nhe I as the
N-terminal restriction site introduces three additional amino acids at the N-terminus.
The generated N-terminus is MAS. The methionine is cleaved of in E.coli and leaves
the N-terminal AS free for Edman sequencing. The gene of MED21 was then inserted,
together with a second ribosomal binding site, at the 5’ region of the MED21 gene
as described (Lutzmann et al., 2002). The design of the primer used can be seen
in Figure 28. The restriction sites used were Sal I and Not I. An additional Nde I
site is inserted at the start site of the MED21 ORF for easier shuffling of the genes.
Bicistronic expression of MED4/MED9 and the tricistrones of MED4/MED9/MED31
and MED7/MED10/MED31 were done in the same way. The exact restriction sites
can be seen in table 8. All S. cerevisiae proteins were amplified from S. cerevisiae
genomic DNA. Constructs encoding for S. pombe proteins were done using S. pombe
cDNA obtained from C. Gustafsson.
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Figure 28: The forward primer used for bicistronic expression: it contains an additional
ribosomal binding site (RBS), The coding sequence of MED21 is underlined.
Point mutations Point mutations were generated to introduce a silent mutation in
the MED21 ORF to remove an internal ribosomal binding site (RBS). MED21 was
mutated to contain additional methionines for structure solution. All point mutations
were introduced by site-directed mutagenesis with the two step PCR-method. The
gene of interest was amplified from the cloned plasmid in two steps. In the first step
an oligonucleotide containing the mutations was used as a reverse primer together
with the forward primer of the gene of interest. In the second step the generated PCR
product -which contains the mutations- was used instead of the forward primer together
with a reverse primer of the gene. The resulting PCR product was digested and ligated
into the corresponding vector.
4.2.3 Expression and purification of middle module proteins
MED7/MED21 variants Plasmids containing different variants of MED7/MED21
were transformed into competent BL21 DE3 (Stratagene) and expressed as described
in 4.1.5. For protein purification cells were thawed at 30◦ C and lysed by 15 min of son-
ication using a flat 1
2
” working tip with 20 % duty time and 40 % output on a Branson
sonifier. The slurry was cleared by 30 min of centrifugation in a SS34 rotor at 4◦ C and
15000 rpm. The complexes containing a His-tag were loaded onto a 3 ml self assem-
bled Ni-NTA agarose column (Qiagen) equilibrated with lysis buffer. After washing
with 30 ml lysis buffer bound protein was eluted with 15 ml lysis buffer containing
200 mM imidazole. Eluted proteins were diluted 1:1 with MonoQ buffer containing
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50 mM NaCl and further purified by anion exchange chromatography (MonoQ 10/100
GL (Amersham)). After binding the column was washed with two column volumes
(CV) of MonoQ buffer containing 50 mM NaCl. Bound proteins were eluted with a
10 CV linear gradient of the same buffer containing 50 mM to 1 M NaCl. After con-
centration, the pooled fractions were applied to a Superose-6 HR gelfiltration column
(Amersham) equilibrated with MED7/MED21 buffer. Peak fractions were analyzed
by SDS-PAGE, combined and concentrated to a final concentration of 16 mg/ml.
For purification of the MED7/MED21 variants without an affinity tag proteins in the
cleared lysate were precipitated by the addition of saturated ammonium sulfate solu-
tion to a final concentration of 35 %. After 30 min of centrifugation at 4◦ C and 12 000
rpm in a SS34 rotor the pellet was dissolved in MonoQ buffer containing 50mM NaCl.
Buffer was added until the conductivity was bellow 100 mS/cm3 and the sample was
further purified in the same way as the affinity purified MED7/MED21 complex.
Purification of tri and tetrameric complexes A plasmid containing the
MED7∆N∆C/MED21His and either MED4His or MED10His were cotransformed
into E. coli BL21 DE3 (Stratagene) and expressed as described (4.1.5). The tetrameric
MED4/MED7/MED9/MED21 complex was obtained by cotransforming a plasmids
containing MED4/MED9 and MED7∆N∆C/MED21His. For all three complexes
the purification procedure of MED7 /MED21 variants was followed until the MonoQ
where elution was done using 20 CV linear gradient and dimeric MED7/MED21 com-
plexes could be separated from trimeric MED4/MED7/MED21 or MED7/MED10/MED21.
Further polishing of the samples was done on a Superose 6 gelfiltration column in
MED7/MED21 buffer as above.
Purification of MED4/MED9 MED4 and MED9 are coexpressed from one single
plasmid in a bicistronic manner. None of the two proteins has an affinity tag. For
purification the cleared lysate was precipitated by the drop wise addition of saturated
ammonium sulfate solution to a final concentration of 25 %. The mixture was stirred
on ice for 30 min and then centrifuged in a SS34 rotor for 30 min at 4◦ C and 12000
rpm. The pellet was dissolved in lysis buffer and remaining debris was removed by an
other centrifugation step (20 min 16000 rpm at 4◦ C). The protein concentration was
determined by Bradford reagent (Biorad).
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Name Description
lysis buffer 150 mM NaCl, 20 mM Tris pH 8.5 (4◦ C), 10mM β-
mercaptoethanol, 1 mM PMSF, 0 to 200mM imidazole
MonoQ buffer 50 mM to 1 M NaCl, 20 mM Tris pH 8.5 (4◦ C), 3mM DTT
ammonium sulfate at room temperature saturated solution of ammonium sul-
fate
Gst buffer 150 mM NaCl, 20 mM Tris pH 7.5 (4◦ C), 10mM DTT, 0
to 100 mM reduced glutathione
MED7/MED21 buffer 150mM NaCl, 20 mM Bicine pH 8.5 (4◦ C), 3 mM DTT
Table 11: Buffers used during the purification of MED7/MED21 variants
Purification of MED7/MED4 A plasmid containing GstMED7 and MED4His was
expressed, cells were harvested and cleared lysate was prepared as described above.
The protein complex was first purified on a Ni NTA sepharose (Qiagen) gravity flow
column due to the His tag on MED4. The eluate of the Ni NTA was adjusted to pH 7.5
by dilution with lysis buffer containing 20 mM Tris pH 7.5 (4◦ C) and 10 mM DTT.
500 µl of Gst beads (CL4B, Amersham) were added to the sample and the mixture was
incubated on a rotating wheel for 4 h at 4◦ C. After three washing steps bound protein
was eluted with 100 mM reduced glutathione in lysis buffer.
MED31 purification MED31 containing a His tag was expressed as described above.
Purification was as for MED7/MED21His except for the Ni affinity step where a 1 ml
HisTrap HP (Amersham) was used. The cleared lysate was loaded onto the preequili-
brated (lysis buffer) HisTrap column on a peristaltic pump at 0.5 ml/min. The column
was washed with Lysis buffer. Bound protein was eluted on a Aekta FPLC system
(Amersham) with a stepwise gradient of 20, 40, and 200 mM imidazole. Elution of
protein was monitored by absorption at 280 nm. Purity of the protein was analyzed
by SDS-PAGE. Further purification was done by anion exchange chromatography and
gelfiltration as above.
4.2.4 Interaction assay
To test interactions of MED31 with other subunits of the middle module a plasmid
containing the gene of MED31 was cotransformed with a plasmid coding for one of
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the following proteins: MED4, MED6, MED7, MED9, MED10 and MED21. Each
of this proteins was cloned such that it contains a his tag except for MED9 which
was cotransformed with MED31His. Protein expression was done as described above,
in small cultures of 50 ml. Cells were harvested by 15 minutes of centrifugation at
4500 rpm in 50 ml falcon tubes in a Haereus centrifuge. Cells were resuspended in
2 ml lysis buffer. For lysis glass beads were added to the suspension and cells were
opened by vigorous shaking for 30 minutes on a home made shaking machine. Non
soluble debris was removed by 3 minutes centrifugation in a micro centrifuge at 14000
rpm. The supernatants were incubated with 30 µl of prewashed Ni NTA matrix for
3h. Beads were pelleted by centrifugation (700 g, in a micro centrifuge) and washed
4 times with lysis buffer. All steps were performed at 4◦ C. Bound proteins were
eluted by the addition of SDS sample buffer, boiled for 5 min at 95◦ C and analyzed
by SDS-PAGE.
4.2.5 Crystallization and crystal treatment
Crystallization Variants of MED7/MED21 were crystallized at 20◦ C with the hang-
ing drop vapor diffusion method using 24 well plates and plastic cover slides (molec-
ular dimensions). An initial crystallization condition of MED7∆N∆C/Med21 stems
from the commercial Hampton crystal screens II and contains 10 % ethanol and 1.5 M
NaCl. This condition could be refined as mentioned in table 11. Mutant MED7∆N∆C
/MED21∆C crystallized in additional 4 conditions in the Hampton screen I (0.4 M
NaK tartrate; 30 % PEG400, 0.1 M Tris pH 8.5, 0.2 M Na citrate; 1 M Na acetate,
0.1 M imidazole pH 6.5; 0.2M Mg formate) and could be optimized as shown in ta-
ble 11. Crystals of higher order complexes of MED10/MED7∆N∆C/MED21 and
MED4/MED7∆N∆C/MED21 were obtained in very similar conditions.
Crystal freezing Crystals obtained in acetate and tartrate were harvested in mother
solution, which was exchanged gradually against mother solution containing additional
35 % glycerol. The gradual exchange of the solutions was done in then steps were
in a first step 1/10 of the drop solution was replaced by cryosolution, in a second
step 1/9 and so on. This steps were done until replacement of 1/2 of the solution,
which was repeated twice to ensure complete replacement of the mothersolution by
the cryosolution. Crystals were flash frozen in liquid nitrogen.
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Crystals of the native and selenomethionine MED7∆N∆C/MED21His complex were
grown in mothersolutions containing ethanol. For freezing of crystals grown in these
conditions the mother solution was exchanged by the same solution containing 25 %
glycerol, but no ethanol, using microdialysis buttons.
4.2.6 X-ray structure determination
Data collection: All diffraction data were collected at the beamline X06SA at the
Swiss Light Source, Villigen, Switzerland. The crystals were radiation sensitive and
diffraction power was rather weak. Therefore images were recorded with maximal
possible detector distance to reduce the background. To further reduce the background
images were collected with an increment of 0.5◦/image. Focusing of the beam on
the detector rather than on the crystal helped to increase the resolution and decrease
radiation damage of the crystal.
For MAD phasing, three additional methionines were introduced at positions of con-
served hydrophobic residues in MED21∆C (L5M/L119M/L125M). MAD experiments
were performed on crystals of selenomethionine-labeled protein, and diffraction data
were processed with DENZO and SCALEPACK (Ottwinowski and Minor, 1996) (Ta-
ble 3).
Structure solution Four selenium sites were correctly identified with program SOLVE
(Terwilliger, 2002), and refined using SHARP (La Fortelle and Bricogne). Three ad-
ditional selenium peaks were detected in residual electron density maps with SHARP.
Phasing with SHARP, using seven consistent peaks, led to an electron density map
that revealed distinct α-helices. A total of ten methionine residues are present in the
amino acid sequences and were ordered in the electron density map, except the two
N-terminal methionines and M42 of MED21. Using the selenium sites as sequence
markers, most of MED7 and MED21 could be built into the electron density map at 3.6
Å resolution with program O (Jones et al., 1991). This initial model was repositioned
in the unit cell of the native crystal by rigid body refinement with CNS (Brunger et al.,
1998). Model-phased maps at the final resolution of 3.0 Å allowed us to complete and
refine the structure with CNS to a free R-factor of 28.9 % (Table 4). The second crys-
tal form, belonging to space group C2221 was phased using the 4-helix bundle of the
refined MED7/MED21 structure. A difference electron density map phased with the
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Variant Crystallization condition Cryo-condition used for
MED7∆N∆C
MED21His
0.8-1.1 M NaCl, 10-
15 % ethanol, 0-3 %
PEG 6000, 10 mM β-
mercaptoethanol, 10 mM
EDTA
0.8-1.1 M NaCl, 25 %
glycerol 0-3 % PEG
6000, 10 mM Bicine
pH 8.5, 10 mM β-
mercaptoethanol, 10
mM EDTA
molecular
replacement,
C2221
MED7∆N∆C
MED21∆C
500 mM sodium acetate,
100 mM Hepes pH 7.5, 5
% PEG 400, 10 mM β-
mercaptoethanol
crystallization con-
dition containing
additionally 35 %
glycerol
native dataset,
phase exten-
sion, P4322
MED7∆N∆C
MED21∆C
100 mM sodium potas-
sium tartrate, 100 mM
Hepes pH 7.5, 5 % PEG
400, 10 mM β-mercapto-
ethanol, 10 mM EDTA
crystallization con-
dition containing
additionally 35 %
glycerol
selenomethionine
derivative,
P4322
MED7∆N∆C
MED10
MED21
0.8 M NaCl, 11 % ethanol,
10 mM β- mercapto-
ethanol, 10 mM EDTA
0.8 M NaCl, 30 %
glycerol, 10 mM Bicine
pH 8.5, 10 mM β-
mercaptoethanol, 10
mM EDTA
molecular
replacement,
C2221
MED7∆N∆C
MED10
MED21
160 mM sodium potas-
sium tartrate, 10 %
ethanol, 10 mM β-
mercaptoethanol, 10 mM
EDTA
160 mM sodium
potassium tartrate, 35
% Glycerol, 10 mM
Bicine pH 8.5, 10 mM
β-mercaptoethanol, 10
mM EDTA
molecular
replacement,
C2221
MED4
MED7∆N∆C
MED21
300mM ammonium ac-
etate, 3 % Isopropanol, 10
mM 10 mM β-mercapto-
ethanol, 10 mM EDTA
300mM ammonium
acetate, 5 % Glyc-
erol, 10 mM Bicine
pH 8.5, 10 mM β-
mercaptoethanol, 10
mM EDTA
Molecular
replacement,
C2221
MED4
MED7∆N∆C
MED21
0.3-0.7 M NaCl, 7 %
ethanol, 10 mM β-
mercaptoethanol, 10 mM
EDTA
0.3-0.7 M NaCl, 35
% glycerol, 10 mM
Bicine pH 8.5, 10 mM
β- mercaptoethanol, 10
mM EDTA
selenomethionine
derivative,
C2221
Table 12: Crystallization solutions of variants of MED7/MED21,
MED4/MED7/MED21 and MED7/MED10/MED21
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bundle domain showed locations of the coiled-coil protrusions in the two heterodimers
of the asymmetric unit that deviated substantially from that observed in the original
structure. The coiled-coil region was adjusted. An extended loop between MED21
helices α1 and α2 that was disordered in the P4322 crystal form was added as poly-
alanine in one of two heterodimers in the asymmetric unit, and the resulting model was
refined to a free R-factor of 31.4 % (Table 4). The MED21 loop α1-α2 is better ordered
in the C2221 crystal form since it forms a crystal contact that is not observed in the
P4322 crystal form. In both refined structures, none of the residues fall in disallowed
regions of the Ramachandran plot (Table 4).
4.3 Reconstitution of the middle module
4.3.1 Expression and purification of the MED7/MED10/MED21/MED30 middle
module complex
Plasmids containing MED7/MED10/MED21 and MED31 were cotransformed into
BL21 DE3 RIL and expressed as described in 4.1.5. For purification of expressed pro-
teins cells were thawed at 30◦ C and lysed by sonication with a Branson sonifier 250
and a flat 1
2
” working tip for 15 min 20 % duty time and 40 % output. The lysate was
then centrifuged for 30 min at 4◦ C and 16000 rpm in a SS34 rotor. The cleared lysate
was loaded onto a preequilibrated 1 ml HisTrap HP (Amersham) column washed with
20 mM of lysis buffer and eluted stepwise with lysis buffer containing 20, 40, 70 and
200 mM imidazole. Protein elution was monitored by absorption at 280 nm and Brad-
ford reagent (Biorad). Eluted fractions were analyzed by 17 % SDS-PAGE. The main
fractions of the 70 mM imidazole elution were diluted with buffer A and loaded on a
MonoQ 10/100 GL (Amersham) anion exchange chromatography column and eluted
with a 20 column volume linear gradient of buffer A containing 50 mM to 1 M NaCl.
The main fractions were analyzed by 17 % SDS-PAGE, pooled and concentrated in
Amicon Ultra centrifugal devices with 10 KDa molecular weight cut off. The con-
centrated samples were loaded onto a Superose 6 10/300 GL (Amersham) gelfiltration
column equilibrated with Buffer B. Peak fractions were analyzed by 17 % SDS-PAGE,
concentrated to 4.5 mg/ml and used for crystallization setups.
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4.3.2 Reconstitution of a MED4/MED7/MED9/MED10/MED21/MED30 middle
module complex
The 40 mM His Trap elution of MED7/MED10/MED21/MED30 was mixed in a 1 to
1.5 ratio with ammonium sulfate purified MED4/MED9 (4.2.3) and the complex was
assembled for 1 h at 20◦ C. After 1h the conductivity was adjusted to less than 100
mS/cm3 by the addition of buffer A and the sample was loaded on a MonoQ 10/100
GL (Amersham). Elution was as for MED7/MED10/MED21/MED30. Pure fractions
were concentrated in Amicon Ultra centrifugal devices (10 KDa molecular weight cut
off) and applied to a Superose 6 10/300 GL (Amersham) gelfiltration column preequi-
librated with buffer B. Peak fractions were analyzed by SDS-PAGE, concentrated to a
final concentration of 5 mg/ml and used for Crystallization setups as well as for Pol II
middle module complex assembly.
4.3.3 Assembly of a Pol II/middle module complex
For reconstitution of a middle module Pol II complex 10 subunit Pol II, Rpb4/Rpb7
and the purified middle module complex are assembled. Pol II and Rpb4/Rpb7 were
obtained from Stefan Benkert. Buffers of 10 subunit Pol II and middle module were
exchanged to Pol II buffer using Amicon Ultrafree-MC centrifugal devices with 100
and 10 KDa cut off, respectively. Rpb4/Rpb7 were obtained frozen in Pol II buffer
and thawed on ice. 10 subunit Pol II, Rpb4/Rpb7, and middle module were combined
and incubated on a rotating wheel at 20◦ C for 1 h prior to gelfiltration on Superose
6 10/300 GL (Amersham). 5 fold excess of Rpb4/Rpb7 and 3 fold Excess of middle
module were used the total volume was adjusted to 200 µl. Peak fractions were ana-
lyzed by 17 % SDS-PAGE, fractions containing the complex were concentrated to 200
µl and reloaded onto a Superose 6 gelfiltration column. The peak fractions were again
analyzed by 17 % SDS-PAGE.
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buffer description
lysis buffer 150 mM NaCl, 20 mM Tris pH 8.5 (4◦ C), 10 mM β-
mercaptoethanol, 1 mM PMSF, 0 to 200 mM imidazole
MonoQ buffer 50 mM to 1 M NaCl, 20 mM Tris pH 8.5 (4◦ C), 10 mM
β-mercaptoethanol
ammonium sulfate at room temperature saturated solution of ammonium sul-
fate
middle module buffer 150 mM NaCl, 20 mM Tris pH 8.5 (4◦ C), 10 mM β-
mercaptoethanol
Pol II buffer 40 mM ammonium sulfate, 5 mM Hepes pH 7.25 10 µM
ZnCl2, 10 mM DTT
Table 13: Buffers used for the purification and reconstitution of the middle module
4.3.4 Gst-CTD pull-down
Gst-CTD pull-downs were done to test binding of the six-subunit middle module com-
plex to the CTD of Pol II. Gst fusion proteins of the CTD repeats only and the CTD
containing the linker domain of Rpb1 were used. Both Gst-CTD constructs as well as
a Gst only control were expressed as described in 4.1.5. The cells were resuspended
in 50 HGN100 buffer and lysed by sonication as described above. After two 30 min-
utes centrifugation steps (SS34, 16000rpm, 4◦ C). 500 µl of prewashed Gst sepharose
(CL4B, Amersham) was added to the cleared lysate. Gst fusion protein was bound
to the beads during 4 hours at 4◦ C on a rotating wheel. The slurry was decanted
into plastic columns (Qiagen) and washed with 20 ml of HEGN100 buffer. Amounts
and purity of the bound protein was analyzed by Bradford and SDS-PAGE. Protein
amounts were equalized by diluting with empty Gst sepharose to a final concentra-
tion of 0.5 µg/µl beads. As a positive control the CTD interacting domain of Pcf11
(residues 1 to 140) was expressed and purified according to (Meinhart and Cramer,
2004). Pcf11 and the reconstituted middle module was dyalized against HEGN100
buffer and incubated with 30µl Gst-CTD beads over night. The beads were washed
for four times with HEGN100, boiled in SDS sample buffer and analyzed by SDS-
PAGE and western blot. The HisProbe system (pierce) was used to detect His-tagged
proteins.
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buffer description
HEGN100 10% glycerol, 100µM EDTA, 20 mM Hepes pH 7.6, 0.1 %
NP40, 100 mM KCl, 1mM PMSF, 5mM DTT
BSA 10 mg/ml solution (Biolabs)
Table 14: Buffers used for the Gst-CTD pull-down
4.4 ACID
4.4.1 Design of ACID variants
Since the fullength ACID is a large protein of 752 amino acids containing two separate
domains connected by a large unordered and strongly charged loop and C-terminus, it
is not suited for crystallization. The approach is therefore to determine the structure of
the activator interaction domain together with the activation domain of VP16. Since
crystallization of the original interaction domain did not yield crystals I used an other
species -Drosophila melanogaster- and designed 4 truncations of the domain. Clusters
of highly charged residues on the protein surface are often inhibiting crystallization.
Therefore putative K and E surface residues were mutated to A. Design of mutations
and truncations was based on results from sequence alignments, secondary structure
prediction and proteolytic digests of the protein.
A first construct containing the activator interaction domain of human ACID amino
acids 393 to 548 was obtained from T. Uhlmann. For cloning of the drosophila ac-
tivator interaction domain of ACID; drosophila cDNA was used. Further constructs
of the human and drosophila proteins were obtained by standard cloning methods us-
ing the plasmid and cDNA as templates. Mutations were introduced by the two step
PCR-method using primers which contain the corresponding mutations. For cloning of
Gst-VP16H1 the plasmid containing the complete VP16 activation domain (404-490)
(Donaldson and Capone, 1992) was used. A premature stop codon after amino acid
451 was inserted by PCR.
4.4.2 Purification of ACID constructs
Affinity purification: Variants containing a His tag were resuspended in lysis buffer
supplemented with 1 mM PMSF and lysed by French press (Gaulin) with 750 Bar
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name species variant size
(AA)
MW PI ε tag
hACIDHis human 393-548 166 19.1KDa 9.6 22310 His
hACID human 393-548 158 18KDa 9.8 22310 none
hACIDHis human 394-543 160 18.12 9.51 22310 His
hACID human 394-543 152 17.06 9.64 22310 none
hACIDHis
K411/413A/D418A
human 394-543 160 17.96 9.44 22310 His
hACID
K411/413A/D418A
human 394-543 152 16.9 9.58 22310 none
hACIDHis
E437/442A/K440A
human 394-543 160 17.95 9.68 22310 His
hACID
E437/442A/K440A
human 394-543 152 16.88 9.8 22310 none
hACIDHis
K478A
human 394-543 160 18.07 9.41 22310 His
hACID
K478A
human 394-543 152 17.0 9.55 22310 none
hACIDHis
K518/519/520A
human 394-543 160 17.95 9.1 22310 His
hACID
K518/519/520A
human 394-543 152 16.89 9.3 22310 none
dACIDHis 1 drosophila 515-674 172 19.6KDa 8.7 19870 His
dACIDHis 2 drosophila 515-687 185 21.2KDa 8.9 19870 His
dACIDHis 3 drosophila 515-656 154 17.4KDa 7.1 19870 His
dACIDHis 4 drosophila 515-663 161 18.3KDa 8.4 19870 His
Table 15: Different variants of drosophila and human Acid, their size, molecular
weight (MW), isoelectric point (PI) and absorption coefficient ε at 280nm.
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pressure. Lysed cells were centrifuged for 30 min at 4◦C in a SS34 rotor at 16000 rpm
to remove cellular debris. The supernatant was loaded twice onto a self assembled
4 ml Ni-NTA agarose (Qiagen) gravity flow column. The column was sequentially
washed with 20 ml of Lysis buffer, 20 ml of Lysis buffer containing 1 M NaCl to re-
move bound DNA, and 20 ml of Lysis buffer containing 10 mM imidazole. Elution
was done using lysis buffer containing 200 mM imidazole and a final concentration of
1 mM of EDTA was added to the eluate to chelate Ni2+ bleeding of the column. For
the variants of the human proteins the eluate of the Ni-NTA was diluted using Source
S buffer containing 50 mM NaCl until conductivity was below 100 mS/cm3 and was
passed over a SourceS (Amersham) column. Bound proteins were eluted with a 10
column volume linear gradient with SourcS buffer containing 50 mM to 1 M NaCl.
Variants of the Drosophila protein were passed over a MonoQ instead of the SourceS
column using the corresponding buffer. The protein containing fractions were ana-
lyzed by SDS-PAGE, concentrated and loaded onto a Superdex 75 HR gelfiltration
column preequilibrated with hACID, dACID or NMR buffer. All fractions were ana-
lyzed by 17 % SDS-PAGE and pure protein fractions were concentrated in 10 KDa cut
off Amicon Ultra centrifugal devices (millipore) to a final concentration of 10 to 16
mg/ml and used for crystallization setups. dACID 3 was concentrated to 19.3 mg/ml
and used for NMR tests.
Purification of variants without an affinity tag: Variants without an affinity tag
were purified by cation exchange chromatography, taking advantage of the strong pos-
itive charge of the domain as shown in table 15. Cells were resuspended in SP buffer
supplemented with 5 mM DTT and 1 mM PMSF and lysed by French Press as de-
scribed above. After lysis and centrifugation the lysate was loaded onto an 5 ml Hitrap
SP HP (Amersham) cation exchange column. The bound proteins were eluted with a
10 column volume linear gradient of buffer SP containing 50 mM to 1 M NaCl. Pro-
tein elution was monitored by absorption at 280 nm, DNA contamination at 260 nm
throughout the whole purification procedure. Protein containing fractions were ana-
lyzed by 17 % SDS-PAGE, the peak fractions pooled and diluted with MonoQ buffer
as above. Care was taken that the pH reached 8.5 before loading onto a MonoQ 10/100
GL (Amersham). The protein containing flow through was concentrated and loaded
onto a Superdex75 10/30 HR as described for the affinity purified ACID. The Pro-
tein containing fractions were analyzed by 17 % SDS-PAGE concentrated to a final
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concentration of 10 mg/ml as above and used for crystallization setups.
4.4.3 Purification of the ACID/VP16 complex
Two plasmids containing the human ACID 393-548 and a Gst-VP16 activation domain
fusion were cotransformed in BL21 (DE3) and expressed as described 4.1.5. Cell
pellets were resuspended in Gst buffer containing 5 mM DTT and 1 mM PMSF lysed
by French press as described above and incubated with 2 ml glutathione beads (CL4B,
Amersham) for 4 h at 4◦ C on a rotating wheel. The suspension was decanted into
an empty column, washed with 20 ml of Gst buffer, followed by a wash of 20ml of
Gst buffer containing 1 M NaCl and eluted with Gst elution buffer containing 50 mM
of reduced glutathione. Alternatively thrombin digestion was performed over night at
4◦ C using 10 U thrombin/mg of protein directly on the column. Thrombin digested
proteins were further purified as above by Ni NTA using lysis buffer to dilute the
sample until a pH of 8.5 was reached. Eluted fractions were concentrated and further
purified by gelfiltration in hACID buffer as above. Peak fractions were concentrated
as above to a final concentration of about 10 mg/ml and used for crystallization setups.
4.4.4 Binding of ACID to Gst-VP16
Binding assays were performed as described in 4.3.4 for pull downs with the Gst-
CTD using 0.5 µg/µl Gst-VP16 H1 and Gst-VP16 H1mutant on glutathione beads
(CL4B, Amersham) and cleared E. coli lysates of 100 ml of overnight culture of the
corresponding ACID variant.
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Buffer Description
Lysis buffer 150 mM to 2 M NaCl, 20 mM Tris-Cl pH 8.5 at 4◦C, 10
mM β -mercaptoethanol, 0 to 200mM Imidazole
MonoQ buffer 50 mM to 1 M NaCl, 20 mM Tris-Cl pH 8.5 at 4◦C, 5 mM
DTT
SoruceS buffer 50 mM to 1 M NaCl, 20 mM Tris pH 7.0 at 4◦ C, 5 mM
DTT
SP buffer 50 mM to 1M NaCl, 20 mM MES pH 6.5 at 4◦ C, 5 mM
DTT
hACID buffer 150 mM NaCl, 10 mM Hepes pH 7.5, 5 mM DTT
dACID buffer 50 mM ammonium sulfate, 10 mM sodium citrate, 5 mM
DTT
NMR buffer 100 mM NaCl, 20 mM Na2PO4 pH 6.5, 10 mM β-
mercapto-ethanol
Gst buffer 150 mM NaCl, 20 mM Hepes pH 7.5, 5 mM DTT
Gst elution buffer 150 mM NaCl, 20 mM Tris pH 8.0 at 4◦ C, 50 mM reduced
glutathione, 5 mM DTT
Table 16: Buffers used during the purification of ACID and ACID VP16 variants
4.4.5 Electrophoretic mobility shift assay
The DNA binding capability of ACID was analyzed by electrophoretic mobility shift
assay (EMSA). In 15 µl of 0.5 x TBE 50 to 200 pMol ACID were incubated with
50 pMol of previously annealed DNA for 1 h at 4◦ C. 5 µl of sample buffer were
added and the sample was loaded on a native 8 % acrylamide gel in 0.5 x TBE buffer.
Electrophoresis was carried out at 70 to 80 Volt at 4◦ C for 1 to 2 h. The gel was
removed and stained for 20 min in SyBr gold (Molecular probes) and visualized by
UV light at 310 nm. After DNA staining protein bands were stained by coomassie.
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DNA: 17mer: TTATTCCCATGGGAATA
19mer: TTTATTCCCATGGGAATAA
21mer: TTTTATTCCCATGGGAATAAA
23mer: TTTTTATTCCCATGGGAATAAAA
25mer: TTTTTTATTCCCATGGGAATAAAAA
0.5 x TBE 89 mM Tris, 89 mM boric acid, 2 mM EDTA
sample buffer 0.5 x TBE. 60 % glycrol, 5 β-mercaptoethanol, 3 %
bromphenolblue
SyBr gold 0.01 % in 0.5 x TBE
Table 17: DNA and buffers used for EMSA
4.4.6 Crystallization of ACID variants
For crystallization trials of the ACID domain the sitting drop method was used. Com-
mercial screens from Hampton (Hampton I, Hampton II, Natrix, Peg/Ion screen) and
Natrix (classic, anion, cation, MPD) were pre-pipeted into 96 well deep well plates.
These were used for setups with a Hydro plus 1 crystallization robot in Nextal conical
96 well crystallization plates. Drops of 0.5 µl of protein (10 to 20 mg/ml) and 0.5 µl of
reservoir solution were mixed. TCEP was used as a reducing agent (0.5 µl 1M stock
solution per 50 µl of reservoir solution).
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MED9 Alignment
Supplementary Material
The C-terminal region of MED9 is conseved. Multiple sequences of the MED9 C-terminus from 
yeast and higher eukaryotes are aligned. Identical and very conserved (L, I) Conserved residues 
are highlighted in dark green. Conserved residues are highlighted in green, light green and yellow 
according to decreasing degree of conservation. The predicted secondary structure 
(PredictProtein) is shown below the alignment as cylinders (helices) and lines (coils). 
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